

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number  
**WO 02/42323 A2**

- (51) International Patent Classification<sup>7</sup>: C07K 14/00 (74) Agents: BOULT WADE TENNANT et al.; Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).
- (21) International Application Number: PCT/EP01/13604
- (22) International Filing Date:  
22 November 2001 (22.11.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0028495.0 22 November 2000 (22.11.2000) GB  
60/252,790 22 November 2000 (22.11.2000) US
- (71) Applicant (for all designated States except US): DEVGEN NV [BE/BE]; Technologiepark 9, B-9052 Gent-Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): NYS, Guy [BE/BE]; Technologiepark 9, B-9052 Gent-Zwijnaarde (BE). PLAETINCK, Geert [BE/BE]; Technologiepark 9, B-9052 Gent-Zwijnaarde (BE). BOGAERT, Thierry [BE/BE]; Technologiepark 9, B-9052 Gent-Zwijnaarde (BE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/42323 A2

(54) Title: FLUORESCENT PROTEINS

(57) Abstract: There is disclosed an isolated nucleic acid molecule encoding a new fluorescent protein which is capable of emitting fluorescence upon irradiation by incident light, wherein said maximal absorbance of incident light is in the range of 440-480nm, and maximal fluorescence emission is in the range of 470-510nm.

WO 02/42323

PCT/EP01/13604

- 1 -

**FLUORESCENT PROTEINS**

The present invention is concerned with fluorescent proteins and, in particular, with nucleic acid  
5 sequences encoding novel fluorescing proteins which have been isolated from coral species.

Fluorescent proteins, such as, green fluorescent protein from the luminescent jelly fish *Aequorea*  
10 *victoria* are extremely useful molecules by virtue of their ability to function as markers for gene expression and protein localisation within living cells. Fluorescent proteins can be produced *in vivo* by biological systems and can therefore be used to  
15 monitor and trace the progress of intracellular events.

In the present invention, the inventors have surprisingly identified completely novel fluorescing  
20 proteins from the coral species Anthozoa which have been sequenced and which can be used for *in vivo* labelling studies.

Therefore, according to a first aspect of the  
25 invention there is provided an isolated nucleic acid molecule encoding a fluorescent protein comprising an amino acid sequence illustrated in any of the polypeptide sequences of figures 3(a) to 3(d). The present inventors have advantageously identified 4  
30 distinct nucleic acid molecules encoding fluorescing proteins which heretofore have not yet been described. In a further aspect, the invention comprises an isolated nucleic acid molecule encoding a protein capable of emitting fluorescence upon irradiation by  
35 incident light, wherein said maximal absorbance of said incident light is in the range 440-480 nm, in

**CONFIRMATION COPY**

WO 02/42323

PCT/EP01/13604

- 2 -

particular 450-475 (maximum of excitation) and maximal fluorescence emission is in the range 470-510 nm, in particular 480-500 nm (maximum of emission).

5 According to the invention, at least 4 different fluorescent proteins (and nucleic acid sequences encoding said proteins) were obtained from species of coral, and in particular from species of coral belonging to the genus *Discosoma* and the genus  
10 *Polythoa*.

In addition, as can be seen from the data given hereinbelow, hybrids of fluorescent proteins derived from two or more different species from the genus  
15 *Polythoa* and/or *Discosoma* may also be used. Such hybrid fluorescent proteins of the invention may be obtained by suitable expression of hybrid (e.g. chimeric) nucleic acid sequences encoding such hybrid proteins, which in turn may for instance be  
20 obtained by suitably combining (two or more parts of) two or more naturally occurring nucleic acids (i.e. cDNAs and/or genes) encoding (native) fluorescent proteins, at least one of which has been obtained from a coral of the species *Polythoa* and/or *Discosoma*  
25 (and/or from another coral). This can be carried out by techniques known per se and/or as further described below, including but not limited to "gene shuffling" techniques.

30 A listing of the clones used in the invention is given in Figure 2. Also, an alignment of some of the clones used herein is given in Figure 8B.

The excitation- and emission-spectra for some of these  
35 proteins are given in the Figures, and are also summarized below:

WO 02/42323

PCT/EP01/13604

- 3 -

	Clone	Source	Mutations	Excitation max (nm)	Emission max (nm)
	pGR7	<i>Polythoa</i> spec.	Q135R	469 (452)	490
5	pGR3	<i>Polythoa</i> spec.	N41D, 3' end	469 (452, 489)	496
	pGR13	<i>Polythoa</i> spec	none	469 (452)	490
	pGR15	Hybrid	none	451 (440)	484

Accordingly, in one embodiment, the invention relates  
10 to a fluorescent protein with an emission spectrum  
which has:

- a maximum of emission (fluorescence - measured  
following excitation at 469 nm) at between 491 and 501  
15 nm, and in particular at about 496 nm;  
and preferably one, and more preferably both, of the  
following:

- an emission at 480 nm (fluorescence - measured  
20 following excitation at 469 nm) of between 30 and 40 %  
of the emission at the maximum of emission;

- an emission at 525 nm (fluorescence - measured  
following excitation at 469 nm) of between 35 and 45 %  
25 of the emission at the maximum of emission;  
and with an excitation spectrum which has:

- a maximum of absorbance (measured at emission at  
490 nm) at between 464 and 474 nm, and in particular  
30 at about 469 nm; and at least any one, preferably at  
least any two, more preferably at least any three, and  
most preferably all four of the following:

- an absorbance at 452 nm (measured at emission at  
35 490 nm) of between 59 and 69 % of the absorbance at  
the maximum of absorbance;



WO 02/42323

PCT/EP01/13604

- 4 -

- an absorbance at 456 nm (measured at emission at 490 nm) of between 54 and 64 % of the absorbance at the maximum of absorbance;
- 5    - an absorbance at 486 nm (measured at emission at 490 nm) of between 42 and 52 % of the absorbance at the maximum of absorbance;
- 10   - an absorbance at 489 nm (measured at emission at 490 nm) of between 63 and 73 % of the absorbance at the maximum of absorbance.

In another embodiment, the invention relates to a fluorescent protein with an emission spectrum which  
15   has:

- a maximum of emission (fluorescence - measured following excitation at 469 nm) at between 485 and 495 nm, and in particular at about 490 nm,  
20   and preferably one, and more preferably both, of the following:
- an emission at 480 nm (fluorescence - measured following excitation at 469 nm) of between 46 and 56 %  
25   of the emission at the maximum of emission;
- an emission at 525 nm (fluorescence - measured following excitation at 469 nm) of between 33 and 43 % of the emission at the maximum of emission;  
30   and with an excitation spectrum which has:
- a maximum of absorbance (measured at emission at 490 nm) at between 464 and 474 nm, and in particular at about 469 nm; and at least any one, preferably at  
35   least any two, more preferably at least any three, and most preferably all four of the following:

WO 02/42323

PCT/EP01/13604

- 5 -

- an absorbance at 440 nm (measured at emission at 490 nm) of between 48 and 58 % of the absorbance at the maximum of absorbance;
- 5    - an absorbance at 452 nm (measured at emission at 490 nm) of between 55 and 65 % of the absorbance at the maximum of absorbance;
- an absorbance at 456 nm (measured at emission at 490 nm) of between 52 and 62 % of the absorbance at  
10   the maximum of absorbance;
- an absorbance at 480 nm (measured at emission at 490 nm) of between 48 and 58 % of the absorbance at the maximum of absorbance.
- 15   In yet another embodiment, the invention relates to a fluorescent protein with an emission spectrum which has:
- 20   - a maximum of emission (fluorescence - measured following excitation at 451 nm) at between 479 and 489 nm, and in particular at about 484 nm, and preferably one, and more preferably both, of the following:
- 25   - an emission at 470 nm (fluorescence - measured following excitation at 451 nm) of between 39 and 49 % of the emission at the maximum of emission;
- 30   - an emission at 525 nm (fluorescence - measured following excitation at 451 nm) of between 31 and 41 % of the emission at the maximum of emission; and with an excitation spectrum which has:
- 35   - a maximum of absorbance (measured at emission at 484 nm) at between 446 and 456 nm, and in particular at about 451 nm; and at least any one, preferably at least any two, more preferably at least any three, and

WO 02/42323

PCT/EP01/13604

- 6 -

most preferably all four of the following:

- 5       - an absorbance at 420 nm (measured at emission at 484 nm) of between 61 and 71 % of the absorbance at the maximum of absorbance;
- an absorbance at 440 nm (measured at emission at 484 nm) of between 86 and 96 % of the absorbance at the maximum of absorbance;
- 10     - an absorbance at 447 nm (measured at emission at 484 nm) of between 84 and 94 % of the absorbance at the maximum of absorbance;
- an absorbance at 470 nm (measured at emission at 484 nm) of between 61 and 71 % of the absorbance at the maximum of absorbance.
- 15

Also, any protein with an emission and/or exitation spectrum as indicated above preferably has a degree of sequence identity with at least one of the proteins encoded by the nucleic acid sequences shown in Figure 1, of at least 70%, preferably at least 80%, more preferably at least 90% and even more preferably at least 95% sequence identity with at least one of the proteins encoded by at least one of the nucleotide sequences depicted in Figure 1, in which the percentage sequence homology is determined as described hereinbelow.

20

25

30     For the some of the clones described hereinbelow, pertinent values are given in Figure 28.

Preferably, the nucleic acid molecule is a DNA and more preferably a cDNA molecule. The cDNA molecules are preferably isolated from the Discosoma or Polythoa

35

WO 02/42323

PCT/EP01/13604

- 7 -

genus of coral although they may also be synthetically prepared using techniques which would be well known to practitioners skilled in the art. Preferably, the nucleic acid sequences encoding the novel proteins are  
5 as set forth in Figure 1.

Preferably, the nucleic acid molecule is substantially homologous to the nucleic acid sequences depicted in Figure 1. Even more preferably the nucleic acid  
10 molecule has at least 70, preferably at least 80, more preferably at least 90 and even more preferably at least 95% sequence identity to at least one of the nucleic acid sequences depicted in Figures 1 and even more preferably comprises any of the nucleic acid  
15 sequences of Figure 1.

The fluorescent proteins of the invention can be used for any application known per se for fluorescent proteins described in the art, such as for the green  
20 fluorescent protein from *Aequorea victoria* mentioned above. Such applications will be clear to the skilled person, and may include, but are not limited to, the applications of such "GFPs" mentioned in the relevant prior art, such as WO 95/07463, WO 97/11094, WO  
25 97/42320, WO 98/06737 and WO 97/41228.

As such, the fluorescent proteins of the invention (and/or the nucleic acid sequences encoding these proteins) may be used as a label and/or marker, and in  
30 particular as a genetic marker and/or an expression marker, for instance in the fields of (micro-)biology, biochemistry and/or molecular biology.

For example, the fluorescent proteins of the

WO 02/42323

PCT/EP01/13604

- 8 -

inventions (and/or the nucleic acid sequences encoding these proteins) may be used in *in vitro* applications, such as hybridisation assays and/or immunological assays (e.g. ELISA's).

5

However, fluorescent proteins of the invention are particularly suited for applications *in vivo*, including but not limited to expression and/or use in bacteria, protozoa, fungi, algae, yeast cells or other  
10 micro-organisms; in (cells or tissues of) plants and/or animals; and/or in cells or cell lines derived from plant cells or animal cells.

One particularly preferred application involves the  
15 expression and use in species of nematode, such as *C.elegans*, e.g. for screens or assays involving the use of such nematodes.

Some other possible applications include, but are not  
20 limited to:

- follow up of a protein tagged with a fluorescent protein during the purification of said protein ( e.g. using chromatography techniques);
- 25 - *in vivo* expression analysis;
- investigation of the transport of proteins etc. across biological membranes; and/or (other)
- 30 qualitative and/or quantitative detection techniques and/or analytical techniques.

The nucleic acid molecules of the present invention are particularly useful in processes for labelling

WO 02/42323

PCT/EP01/13604

- 9 -

polypeptides of interest, e.g., by the construction of genes encoding fluorescent fusion proteins.

Fluorescence labelling via gene fusion is site-specific and eliminates the present need to purify the  
5 labelled proteins *in vitro* and microinject them into cells. Sequences encoding the fluorescing proteins of the present invention may be used for a wide variety of purposes as are well known to those working in the field. For example, the sequences may be employed as  
10 reporter genes for monitoring the expression of the sequence fused thereto; unlike other reporter genes, the sequences require neither substrates nor cell disruption to evaluate whether expression has been achieved. Similarly, the sequences of the present  
15 invention may be used as a means to trace lineage of a gene fused thereto during the development of a cell or organism. Further, the sequences of the present invention may be used as a genetic marker; cells or organisms labelled in this manner can be selected by  
20 e.g. fluorescence-activated cell sorting. The sequences of the present invention may also be used as a fluorescent tag to monitor protein expression *in vivo* and/or *in vitro* or to encode donors or acceptors for fluorescence resonance energy transfer. Other  
25 uses for the sequences of the present invention would be readily apparent to those working in the field, as would appropriate techniques for fusing a gene of interest to an oligonucleotide sequence of the present invention in the proper reading frame and in a  
30 suitable expression vector so as to achieve expression of the combined sequence.

Similarly fusion proteins including an antibody fused to the fluorescing protein may also be generated for

WO 02/42323

PCT/EP01/13604

- 10 -

in vivo labelling, for example. In such an embodiment the nucleic acid molecule of the invention encoding the fluorescing protein will be operably linked to the sequence encoding the antibody. As would be well  
5 known in the art only a small portion of an antibody molecule, the paratope, is involved in binding to the epitope of a protein and a nucleic acid molecule encoding the paratope may be used to generate a labelled molecule specific for the paratope of  
10 interest.

A fusion protein of the 3' sequence of Discosoma coupled to the 5' sequence of Polythoa 2 was also generated using the nucleic acid sequences encoding  
15 the Polythoa 2 and Discosoma 1 protein, for expression in a prokaryotic and eukaryotic expression system, which protein sequences are illustrated in Figure 7. The plasmid pGR15 encoding the sequence of the Polythoa 2-Discosoma 1 hybrid was the vector used for  
20 expression of the fusion protein in *E.coli*, whereas plasmid pGR18 was utilised for eukaryotic expression in COS cells. Plasmid pGR20 was used for expression in *C.elegans* and transformation of the relevant cells or organism using these vectors resulted in expression  
25 of a fluorescing protein.

As outlined in more detail in the examples below, mutant or hybrid proteins were also developed to investigate their absorbance and emission spectra  
30 compared to the wild type Polythoa and Discosoma proteins. The proteins and polypeptides encoded by plasmids pGR3 and pGR7 described herein contain a 109 thioredoxin associated fragment in fusion with the Polythoa 2 fluorescing protein. Furthermore, plasmid

WO 02/42323

PCT/EP01/13604

- 11 -

pGR7 encodes a protein with the mutation Q136R while a further plasmid pGR10 expresses a I106T mutant.

5 An antisense molecule capable of hybridising to the nucleic acid molecules of the invention under conditions of high stringency also forms part of the invention.

10 Stringency of hybridisation as used herein refers to conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrids.  $T_m$  can be approximated by the formula:

15 
$$81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+] + 0.41 (\% \text{G\&C}) - 600/l$$

wherein  $l$  is the length of the hybrids in nucleotides.  $T_m$  decreases approximately by 1-1.5°C with every 1% decrease in sequence homology.

20

The term "stringency" refers to the hybridisation conditions wherein a single-stranded nucleic acid joins with a complementary strand when the purine or pyrimidine bases therein pair with their corresponding base by hydrogen bonding. High stringency conditions 25 favour homologous base pairing whereas low stringency conditions favour non-homologous base pairing.

30

"Low stringency" conditions comprise, for example, a temperature of about 37°C or less, a formamide concentration of less than about 50%, and a moderate to low salt (SSC) concentration; or, alternatively, a temperature of about 50°C or less, and a moderate to high salt (SSPE) concentration, for example 1M NaCl.



WO 02/42323

PCT/EP01/13604

- 12 -

"High stringency" conditions comprise, for example, a temperature of about 42°C or less, a formamide concentration of less than about 20%, and a low salt (SSC) concentration; or, alternatively, a temperature of about 65°C, or less, and a low salt (SSPE) concentration. For example, high stringency conditions comprise hybridization in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C (Ausubel, F.M. et al. Current Protocols in Molecular Biology, Vol. I, 1989; Green Inc. New York, at 2.10.3).

"SSC" comprises a hybridization and wash solution. A stock 20X SSC solution contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0.

"SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 9mM Na<sub>2</sub>HPO<sub>4</sub> and 1 mM EDTA, pH 7.4.

However, other conditions and reagents also result in stringent hybridisation conditions and these are generally well known to the skilled practitioner (Molecular Cloning A Laboratory Manual, J. Sambrook et al., Cold Spring Harbour Press, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons Inc., New York.

As would be appreciated by those skilled in the art, the presence of introns in a nucleic acid sequence can lead to enhanced expression levels. One of the preferred nucleic acid molecules of the invention, the sequence of which is depicted in Figure 2(b), includes a synthetic intron in addition to a 5' UTR including a

WO 02/42323

PCT/EP01/13604

- 13 -

Kozak site.

Fluorescent proteins or functional equivalents,  
fragments or variants thereof encoded by the nucleic  
5 acid molecules of the invention also form part of the  
invention. Furthermore, according to an even further  
aspect, the invention comprises an isolated  
fluorescent protein capable of emitting fluorescence  
upon irradiation by incident light wherein the maximal  
10 absorbance of said incident light is in the range 440-  
480 nm, in particular 450-475 nm (maximum of  
excitation) and maximal fluorescence emission is in  
the range 470-510 nm, in particular 480-500 nm  
(maximum of emission). The invention also comprises  
15 an isolated fluorescent protein comprising an amino  
acid sequence which has at least 70, preferably at  
least 80, more preferably at least 90 and even more  
preferably at least 95% sequence identity to the amino  
acid sequence depicted in any of Figures 3 to 8.

20 Functional equivalents, fragments or variants of the  
polypeptide of the invention are those molecules that  
retain the distinct fluorescing capability of the  
polypeptides of the invention.

25 The DNA molecules according to the invention may,  
advantageously, be included in a suitable expression  
vector to express the fluorescent protein encoded  
therefrom in a suitable host. Incorporation of cloned  
30 DNA into a suitable expression vector for subsequent  
transformation of said cell and subsequent selection  
of the transformed cells is well known to those  
skilled in the art as provided in Sambrook et al.  
(1989), Molecular Cloning, A Laboratory Manual, Cold

WO 02/42323

PCT/EP01/13604

- 14 -

Spring Harbour Laboratory Press.

An expression vector according to the invention includes a vector comprising a nucleic acid according to the invention operably linked to regulatory sequences, such as promoter regions, that are capable of effecting expression of said DNA fragments. The term "operably linked" refers to a juxta position wherein the components described are in a relationship permitting them to function in their intended manner. Such vectors may be transformed into a suitable host cell to provide for expression of a polypeptide according to the invention. Thus, in a further aspect, the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides.

The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, and optionally a promoter for the expression of said nucleotide sequence and optionally a regulator of the promoter. The vectors may contain one or more selectable markers, such as, for example, ampicillin resistance.

The precise nature of the regulatory sequences needed for expression of the fluorescing protein can vary between species or cell types. They will, however, generally include 5' non-transcribing and 5' non-

WO 02/42323

PCT/EP01/13604

- 15 -

translating sequences involved in initiation or regulation of transcription and translation respectively. Regulatory elements required for expression generally include promoter sequences to  
5 bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector may include a promoter such as the lac promoter and for translation initiation the Shine-Dalgarno sequence and the start  
10 codon AUG. Similarly, a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be  
15 obtained commercially or assembled from the sequences described by methods well known in the art.

Nucleic acid molecules according to the invention may be inserted into the vectors described in an antisense  
20 orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

As discussed in the examples provided it is desirable  
25 to enhance the performance or expression levels of the fluorescent proteins in organisms or cells other than those from the coral species from which the proteins or polypeptides of the invention are derived. Every organism adopts a preferred codon usage which is  
30 related to the presence and expression of tRNA genes and which involves post-transcriptional expression regulation. Such optimal codon usage has been determined for a number of organisms. In the present embodiment a vector was generated for optimal

WO 02/42323

PCT/EP01/13604

- 16 -

expression in the nematode *C.elegans*. Therefore, when the host to be transfected with a vector including the nucleic acid molecules of the invention is *C.elegans*, the vector may comprise the plasmid pGR10, described in the example below, which includes the nucleotide sequence depicted in Figure 2(a).

Similarly, the introduction of synthetic introns can result in enhancements of expression levels. A preferred nucleic acid molecule including such a synthetic intron for increased expression levels in *C.elegans* is particularly preferred, which molecule is described in Figure 2(b).

Preferred vectors according to the invention comprise the plasmids designated pGR3, pGR4, pGR5, pGR6, pGR7 and pDW2700, the sequences of which are illustrated in Figures 9 to 14 respectively. Other preferred plasmids according to the invention comprise plasmids designated pGR1, pGR8, pGR13, pGR14, pGR15, pGR16, GR17, pGR18, pGR19, pGR20 and pGR10 identified in the example provided, and which would be readily producible by the skilled practitioner using the method steps described.

In accordance with the present invention, a defined nucleic acid includes not only the identical nucleic acid but also any minor base variations including in particular, substitutions in cases which result in a synonymous codon (a different codon specifying the same amino acid residue) due to the degenerate code in conservative amino acid substitutions. The term "nucleic acid sequence" also includes the complementary sequence to any single stranded sequence

WO 02/42323

PCT/EP01/13604

- 17 -

given regarding base variations.

The present invention also advantageously provides nucleic acid sequences of at least approximately 10  
5 contiguous nucleotides of a nucleic acid according to the invention and preferably from 10 to 50 nucleotides of the nucleic acid sequences set forth in Figures 1 and 2. These sequences may, advantageously be used as probes or primers to initiate replication, or the  
10 like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the invention.  
15 These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting for the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.

20 Letters utilised in the sequences according to the invention which are not recognisable as letters of the genetic code signify a position in the nucleic acid sequence where one or more of bases A, G, C or T can  
25 occupy the nucleotide position. Representative letters used to identify the range of bases which can be used are as follows:

30 M: A or C  
R: A or G  
W: A or T  
S: C or G  
Y: C or T  
K: G or T

WO 02/42323

PCT/EP01/13604

- 18 -

V: A or C or G

H: A or C or T

D: A or G or T

B: C or G or T

5

N: G or A or T or C

According to the present invention, degenerate primers were utilised to fully identify the sequence of the nucleic acid encoding the proteins of the invention.

10 Those novel molecules as described in the example provided also form part of the present invention.

According to the present invention these probes may be anchored to a solid support. Preferably, they are  
15 present on an array so that multiple probes can simultaneously hybridize to a single biological sample. The probes can be spotted onto the array or synthesised *in situ* on the array. (See Lockhart et al., Nature Biotechnology, vol. 14, December 1996  
20 "Expression monitoring by hybridisation to high density oligonucleotide arrays". A single array can contain more than 100, 500 or even 1,000 different probes in discrete locations.

25 The nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as for example using PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 10 to 50  
30 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a suitable biological source, and in particular from (a cell of) a species of coral, more particularly from (a cell of) a species

WO 02/42323

PCT/EP01/13604

- 19 -

of coral from the genus *Polythoa* and/or the genus *Discosoma*, performing a polymerase chain reaction under conditions which brings about amplification of the desired region, isolating the amplified region or  
5 fragment and recovering the amplified DNA. Some of the primers suitable for the aforementioned method include, but are not limited to, the individual primers mentioned in Table 1 as well as the combinations thereof mentioned in Table 2. Generally,  
10 such techniques are well known in the art, such as described in Sambrook et al. (Molecular Cloning: a Laboratory Manual, 1989). Another suitable technique involves "gene shuffling" (DNA shuffling by random fragmentation and reassembly: *In vitro* recombination  
15 for molecular evolution: Proc. Natl. Acad. Sci. Vol 91, pp 10747-10751, October 1994.

Therefore, it is also envisaged that - based upon the disclosure herein and (for instance) using one or more  
20 of the primers listed in Table 1 or a suitable combination thereof (including but not limited to the combinations mentioned in Table 2 - the skilled person will be able to isolate (nucleic acids encoding) additional fluorescent proteins of the invention from  
25 other suitable biological sources, and in particular from other species of coral such as (other) species from the genus *Polythoa* and/or the genus *Discosoma*; and such (nucleic acids encoding such) additional fluorescent proteins are also within the scope of the  
30 present invention.

In one preferred embodiment, such any nucleic acids will have at least 70%, preferably at least 80%, more preferably at least 90% and even more preferably at



WO 02/42323

PCT/EP01/13604

- 20 -

least 95% sequence identity with at least one of the nucleotide sequences depicted in Figure 1, in which the percentage sequence homology is determined as described above; and/or is capable of hybridizing with  
5 at least one of the nucleotide sequences depicted in Figure 1 under conditions of high stringency, again as described above.

The term "homologous" describes the relationship  
10 between different nucleic acid molecules or amino acid sequences wherein said sequences or molecules are related by partial identity or similarity at one or more blocks or regions within said molecules or sequences. Homology may be determined by means of  
15 computer programs known in the art.

Substantial homology preferably carries with it that the nucleotide and amino acid sequences of the fluorescent proteins of the invention comprise a  
20 nucleotide and amino acid sequence fragment, respectively, corresponding and displaying a certain degree of sequence identity to the sequences set forth in Figures 1 and 2 for the nucleotide sequences and 3 to 8 for the polypeptide sequences. Preferably they  
25 share an identity of at least 30 %, preferably 40 %, more preferably 50 %, still more preferably 60 %, most preferably 70%, and particularly an identity of at least 80 %, preferably more than 90 % and still more preferably more than 95 % is desired with respect to  
30 the nucleotide or amino acid sequences depicted in Figures 1 to 8 respectively. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global

WO 02/42323

PCT/EP01/13604

- 21 -

sequence alignment, can be determined using, for example, the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6 (1990), 237-245.) In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Further programs that can be used in order to determine homology/identity are described below and in the examples. The sequences that are homologous to the sequences described above are, for example, variations of said sequences which represent modifications having the same biological function, in particular encoding proteins with the same or substantially the same receptor specificity, e.g. binding specificity. They may be naturally occurring variations, such as sequences from other mammals, or mutations. These mutations may occur naturally or may be obtained by mutagenesis techniques. The allelic variations may be naturally occurring allelic variants as well as synthetically produced or genetically engineered variants. In a preferred embodiment the sequences are derived from a human.

A further aspect of the invention provides host cells transformed or transfected with a vector according to the invention. Such cells can be of prokaryotic or eukaryotic origin. Suitable prokaryotes include gram positive or negative organisms including *E.coli*, *Bacillus* spp, *Pseudomonas* spp, or *salmonella typhimurium*. The expression vector used to transform the prokaryotic cells, and particularly *E.coli*, preferably comprises plasmids designated pGR3 and pGR7, the sequences of which are illustrated in Figure

WO 02/42323

PCT/EP01/13604

- 22 -

9 and 13 respectively. Eukaryotic organisms include yeasts or fungi and plant cells which utilise a transfection system based on infection by *Agrobacterium tumefaciens*.

5

The vectors can also be used to transform cells in tissue culture in addition to non-human organisms and these also form part of the invention. Typical mammalian tissue culture cells include COS-7, HEK-293, BHK, CHD, HELA cells and the like. Suitable organisms which may be useful to monitor expression of proteins using the novel fluorescing proteins of the invention include *C.elegans*, which is particularly advantageous as the fluorescing protein can be viewed *in vivo*.

15

When the organism to be transformed with the appropriate vector is *C.elegans*, the vector preferably comprises the sequence of the plasmid illustrated in Figure 12 or a vector adapted for expression of heterologous proteins in the *C.elegans* including the nucleotide sequences illustrated in Figure 2.

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E.coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the  $\text{CaCl}_2$  method by procedures well known in the art. Alternatively,  $\text{MgCl}_2$  or  $\text{RbCl}$  can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

25  
30

WO 02/42323

PCT/EP01/13604

- 23 -

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransfected with DNA sequences encoding the fusion polypeptide, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the proteins (*Eukaryotic Viral Vectors*, Cold Spring Harbour Laboratory, Gluznan ed., 1982).

Also encompassed within the scope of the present invention is a method of producing a polypeptide according to the invention comprising cultivating a host cell or tissue transformed or transfected with the appropriate vector of the invention under conditions suitable for expression of the fluorescent protein and optionally recovering the expressed protein. The protein may be recovered and purified from the recombinant cell cultures by methods known in the art, including ammonium sulfate or ethanol precipitation acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography and lectin chromatography.

In a further aspect, the invention also comprises an oligonucleotide probe or primer, and which comprises a sequence that selectively hybridises to a nucleic acid

WO 02/42323

PCT/EP01/13604

- 24 -

molecule according to the invention. The oligonucleotide preferably comprises a sequence of at least 10 contiguous nucleotides and is preferably between 10 and 50 nucleotides in length.

5

Advantageously, the novel proteins of the invention, as aforementioned, are particularly useful for monitoring expression of proteins within biological systems and the subcellular localisation or

10 trafficking of proteins. To determine the expression pattern of a particular protein of interest it suffices in principle to make a fusion between the promoter of the gene of interest and the sequence encoding the fluorescing protein. Upon introduction

15 of a vector with the promoter-fluorescent protein of the invention fusion into a cell or organism, any expression induced by the promoter can easily be monitored by following the expression of the protein of the invention. To monitor the subcellular

20 expression of a protein it generally suffices to make a fusion between the protein of interest and the GFP protein, which can be done at either the N or C terminals of the protein.

25 Therefore, in a further aspect the present invention comprises a method for selecting cells capable of expressing a protein of interest, comprising introducing into said cells a vector comprising the nucleotide sequence of a fluorescent protein according

30 to the invention operatively linked to a promoter or regulatory region of the protein of interest, cultivating the cell under conditions necessary for expressing the protein of interest and monitoring for any fluorescent following expression of said

WO 02/42323

PCT/EP01/13604

- 25 -

fluorescent protein.

In accordance with the present invention, a protein of interest includes any protein to be monitored or  
5 labelled by virtue of being attached or expressed together with the proteins of the invention. The techniques for generating fusion proteins using the proteins of the invention are well known to those in the art.

10 A particular use of fluorescent proteins consists of the construction of a synthetic protein harboring a donor fluorescent protein and an acceptor fluorescent protein, connected with a binding protein moiety. The  
15 two fluorescent proteins change conformation upon binding of an analyte to the binding protein moiety. The binding protein moiety has an analyte-binding region which binds an analyte and causes the indicator to change conformation upon exposure to the analyte.  
20 The donor fluorescent protein is covalently coupled to the binding moiety. The acceptor fluorescent protein moiety is also covalently coupled to the binding protein moiety. In the fluorescent indicator the donor moiety and the acceptor moiety change position relative to each other when the analyte binds to the  
25 analyte binding region, altering fluorescence resonance energy transfer between the donor moiety and the acceptor moiety when the donor moiety is excited. Such a system has been described previously by Tsien  
30 et al. WO 98/40477 and Garman WO 94/28166. These molecules are very efficient in measuring internal concentrations of analytes such as cAMP,  $\text{Ca}^{2+}$ , etc. as for measurement of internal enzymatic activities of enzymes such as proteases, esterases, etc. The novel

WO 02/42323

PCT/EP01/13604

- 26 -

fluorescent proteins according to the present invention and functional equivalents, derivatives or fragments thereof can be used to develop new FRET molecules.

5

Therefore, in a further aspect the present invention comprises a method for producing fluorescence resonance energy transfer comprising; providing an acceptor molecule comprising a fluorescent protein  
10 according to the invention providing an appropriate donor molecule for the fluorescent protein; and bringing the donor molecule and acceptor molecule into sufficiently close contact to allow fluorescence resonance energy transfer. Alternatively, the donor  
15 molecule can be the fluorescent protein of the invention in which case an appropriate acceptor molecule for the fluorescent protein is provided.

20 The invention may be more clearly understood from the following description of an exemplary embodiment with reference to the accompanying Figures wherein:

Figure 1 is an illustration of the nucleotide sequences encoding for fluorescent  
25 proteins from the *Polythoa* and *Discosoma* species of coral.

Figure 2 (a) is an illustration of the sequence of the DNA fragment encoding *Polythoa* 2 protein with optimal codon usage for expression in *C.elegans*.  
30 (b) is an illustration of the sequence from (a) further including introns and a 5' untranslated region containing a Kozak

WO 02/42323

PCT/EP01/13604

- 27 -

sequence.

5           Figure 3(a-d) is an illustration of the polypeptide sequences of Polythoa 1 and 2 and Discosoma 1 and 2 encoded by the nucleic acid molecules of the invention.

10           Figure 4 is an illustration of the sequence of a Polythoa fusion protein encoded by plasmid pGR3 and which includes a 109 amino acid thioredoxin fragment fused to the Polythoa 2 polypeptide sequence.

15           Figure 5 is an illustration of the sequence of a Polythoa 2 fluorescent fusion protein in pGR7 which also incorporates the 109 thioredoxin amino acid fragment.

20           Figure 6 is an alignment of the proteins encoded by the plasmids indicated A-J therein.

25           Figure 7 is a further alignment of the protein sequences of the Polythoa 2, Discosoma 1 hybrid and the proteins encoded by the plasmids indicated therein.

30           Figure 8 (a) is a further alignment of the translation products from the DNA fragments indicated therein.

            Figure 8 (b) is an alignment of some of the clones used in the present invention.



WO 02/42323

PCT/EP01/13604

- 28 -

- Figure 9 is an illustration of the nucleotide sequence of plasmid pGR3.
- 5 Figure 10 is an illustration of the nucleotide sequence of plasmid pGR4.
- Figure 11 is an illustration of the nucleotide sequence of plasmid pGR5.
- 10 Figure 12 is an illustration of the nucleotide sequence of plasmid pGR6.
- Figure 13 is an illustration of the nucleotide sequence of plasmid pGR7.
- 15 Figure 14 is an illustration of the nucleotide sequence of plasmid pDW2700.
- 20 Figure 15 is a graphic representation of the emission spectrum of the thioredoxin-FP-fusion protein from pGR3 at (a) 452 nm and (b) 489 nm excitation.
- 25 Figure 16 is a graphic representation of the emission spectrum of thioredoxin-FP-fusion protein from pGR3 at 469 nm excitation.
- 30 Figure 17 is a graphic representation of the pGR3 excitation spectrum at an emission of 490 nm.
- Figure 18 is a graphic representation of the excitation spectrum of thioredoxin-FP-

WO 02/42323

PCT/EP01/13604

- 29 -

fusion protein from pGR7 at 490 nm emission.

5      Figure 19      is a graphic representation of the emission spectrum of thioredoxin-FP-fusion protein from pGR7 at 452 nm excitation.

10      Figure 20      illustrates combined emission and excitation spectra of thioredoxin-FP-fusion protein from pGR7.

15      Figure 21      is a graphic representation of the emission spectrum of thioredoxin-FP-fusion protein from pGR13 at 452 nm excitation.

20      Figure 22      is a graphic representation of the emission spectrum of thioredoxin-FP-fusion protein of pGR13 at 469 nm excitation.

25      Figure 23      is a graphic representation of the excitation spectrum of the thioredoxin-FP-Fusion proteins from pGR13 at 490 nm emission.

30      Figure 24      is a graphic representation of the emission spectrum of thioredoxin-FP-fusion protein pGR15 at (a) 489 nm excitation and (b) 451 nm excitation.

Figure 25      is a graphic representation of the emission spectrum of thioredoxin-FP-

WO 02/42323

PCT/EP01/13604

- 30 -

fusion protein pGR15 at 440 nm  
excitation.

5      Figure 26      is a graphic representation of the  
                         emission spectrum of thioredoxin-FP-  
                         fusion protein pGF15 at 440 nm  
                         excitation.

10      Figure 27      is a list of the clones used in  
                         accordance with the invention.

                 Figure 28      is a list of pertinent absorbance and  
                         emission values for some of the clones  
                         used.

15

**Examples:**

1)      Isolation of cDNA encoding for new fluorescent  
                 proteins

20

a) Isolation of RNA

                 Two brightly fluorescent Anthozoa species  
                 (Polythoa and Discosoma species) were used to isolate  
25      fluorescent proteins. This type of coral can be  
                 obtained from aquarium supply outlets, but such corals  
                 can be obtained from various coral reefs. The corals,  
                 and more particularly the polyps expressing high  
                 levels of fluorescent protein were flash-frozen in  
30      liquid nitrogen. Methods to isolate material samples  
                 are common in molecular biology techniques, and have  
                 been described in "Current Protocols in Molecular  
                 Biology", ed. by Ausubel et al., John Wiley & Sons,  
                 Inc.

WO 02/42323

PCT/EP01/13604

- 31 -

Total RNA was isolated using TRIzol™ Reagent (Cat. NO. 15596; Life Technologies), according to the manufacturers procedure, from the frozen specimens and the total RNA was finally re-suspended in DEPC water  
5 (Current protocols in Molecular biology, ibid).

b) First strand cDNA synthesis

First strand cDNA was prepared using the total  
10 RNA isolations as described above from the Polythoa or the Discosoma species. Random primers were provided by Life Technologies (Cat. NO. 48190-11) and cDNA was synthesized using the Superscript II kit (Cat. NO. 18064-022; Life Technologies). The protocol to  
15 generate cDNA, by RT-PCR was performed according the instructions of the manufacturers.

c) PCR with degenerate primers:

To isolate full cDNA sequences encoding for new  
20 fluorescent proteins, a series of PCR procedures were performed using the cDNA isolated as described above. For these experiments, the following synthetic degenerate primers were used:

oGR1: CACCACATGGAAGGAWRYKTNRAYGG;  
25 oGR2: ACCACATGGAAGGATGCKTNRAYGGNCA;  
oGR3: AATTGTGATCAAGGGCRARGGNRWNGG;  
oGR4: GTGATCAAAGGTGGACCNVTNCCNTT;  
oGR5: GACATATTGTCAACAGAGTTYMANTAYG;  
oGR6: CATATTGTCAACAGAGTTYMANTAYGG;  
30 oGR7: ATCCTGACGACATAACAGAYTAYHWNAA;  
oGR8: GACTATTTCAAGCAGTCGKYCCNGMNNGG;  
oGR9: CATGGGAAAGGTCCTTGCAITWYGARGA;  
oGR10: GGTGACATCTCCTTTCARNAYNCC;  
oGR11: CATATTCTCAGTGGANGSNTCCCA;

WO 02/42323

PCT/EP01/13604

- 32 -

oGR12: CACAGGTCCATCGSNAGGRAARTT;  
oGR13: CCATCGGCAGGAAARTTNANNCC;  
oGR14: TGAATACCCTGTTTCRTANTKRAA

- 5 The first strand cDNAs as isolated above were subjected to PCR amplification using the set of degenerate primers (oGR1 till oGR14) and Amplitaq Gold (Perkin Elmer) as Polymerase. Concentrations, buffers were as provided by the manufacture or minor
- 10 modifications were applied as known in the art. ---  
The PCR conditions were as followed:  
An initial denaturation step at 95°C for 10', followed by 25 cycles of touch down PCR (30" at 95°C, 1' at 55°C (-0.2°C/cycle) and 1' at 72°C) and followed by 15
- 15 cycles of PCR (95°C for 30", at 50°C for 1' and 72°C for 1'). The resulting PCR products were analyzed on standard agarose gel and the DNA fragments of interest were isolated and cloned into vector pCR-XL-TOPO vector (Cat. NO. K4700-20; Invitrogen).
- 20 Following primer combinations resulted in the isolation of appropriate DNA fragments  
On Polythoa first strand cDNA:  
oGR1/oGR14, oGR6/oGR11, oGR2/oGR11, oGR3/oGR11,  
oGR4/oGR11, oGR5/oGR11, oGR1/oGR11,
- 25 on Discosoma first strand cDNA:  
oGR1/oGR10, oGR1/oGR11, oGR6/oGR10, oGR6/oGR11,  
oGR2/oGR11  
oGR1/oGR12, oGR1/oGR14, oGR6/oGR12, oGR6/oGR13, oGR3/  
oGR11, oGR4/oGR11, oGR5/oGR11, oGR8/oGR11, oGR9/oGR11
- 30 It would be apparent to a person skilled in the art that other primer combinations will also result in the isolation of DNA fragments encoding for fluorescent proteins, such as the primer combinations. oGR1/oGR13,

WO 02/42323

PCT/EP01/13604

- 33 -

oGR2/oGR10, oGR2/oGR12, oGR2/oGR13, oGR2/oGR14,  
oGR3/oGR10, oGR3/oGR12, oGR3/oGR13, oGR3/oGR14,  
oGR4/oGR10, oGR4/oGR12, oGR4/oGR13, oGR4/oGR14,  
oGR5/oGR10, oGR5/oGR12, oGR5/oGR13, oGR5/oGR14,  
5 oGR7/oGR10, oGR7/oGR11, oGR7/oGR12, oGR7/oGR13,  
oGR8/oGR10, oGR8/oGR12, oGR8/oGR13, oGR9/oGR10,  
oGR9/oGR12, oGR9/oGR13.

c) establishing bona fide sequences.

10

After initial sequencing of the cloned DNA fragments, more specific primers were designed to isolate the relevant cDNA from the two species.

For the Polythoa species:

15 oGR21:AAAGGCGTGCCCCTTCCTTTCGCTTTCGA;  
oGR22:TGTCAACAGCATTCCAGTATGGCAACAGGGTA;  
oGR23:TGAAGAGGGCGTTTGCACCACAAAGAGTG;  
oGR24:AAAGGGGAGAAGCTTGACCCCAACGGCC;  
oGR25:TTGAAAGCAGTCTGGTTGGCCTTTCTTGA;  
20 oGR26:TGTGGTGCAAACGCCCTCTTCATATTTGAA;  
oGR27:CCCTGTTGCCATACTGGAATGCTGTTGAC;  
oGR28:AAGGAAGGGGCACGCCTTTAGTGACTGTAAG  
oGR29:CTTGCCCTGTCCCTCTCCCGTGATCGTGA;

For the Discosoma species:

25 oGR39:GGAGAAGGAGAAGGAAAACCATACGAGGG;  
oGR40:CCAGTACGGCAACAGGGCATTACCAAAT;  
oGR41:GGGAAAGAACCATGAATTTGAAGACGGG;  
oGR42:CCCCCATTTGGCCCAGTTATGCAGAAGAA;  
oGR43:GCCAATGGGGGGAAAGTTCGCACCATCAA;  
30 oGR44:CGCCCCCGTCTTCAAAATTCATGGTTCTT;  
oGR45:CCTGTTGCCGTACTGGAACGCTGTTGTCA;  
oGR46:TGGGAAGTCTTATGATGGCACCATAACCG;  
oGR47:TTCAGGTAACCAAGGGTGGACCTCTGCCA;  
oGR48:TGTCAGGCATCCCGAAGACATCGCTGATT;

WO 02/42323

PCT/EP01/13604

- 34 -

oGR49: CATGCACTTTGAAGACGGTGGCGTGTGTT;  
oGR50: TCATTGGTGATACAACACACGCCACCGTC;  
oGR51: CATGACCCTTTCCCATGTAAATCCTTCGGGA;  
oGR52: TTGTGGTGACAAAATAGGCCAAGCAAATGGC;  
5 oGR53: GAAATAAAAGGCGACGGTCACGGGAAGCC;  
oGR54: CATGGTAACCAAGGGTGGACCCCTGCCAT;  
oGR55: AAANCTGTCTTTCCCGAGGGATTACAT;  
oGR56: TGGCGTGATTTCAGCNCCAATGATATCA;  
oGR57: CGCCACCGNCTTCAAAGTGCATGACCCTT;  
10 oGR58: ANCGGCTATGTCTTCAGGGTGCTTGACAA  
oGR59: GGTCCACCCTTGGTTACCATGAGCTTGACGTT.

Following primer combinations are to be envisaged:  
oGR21/oGR20, oGR22/oGR20, oGR23/oGR20, oGR24/oGR20,  
15 oGR25/oGR30/OGR31, oGR26/oGR30/OGR31,  
oGR27/oGR30/OGR31, oGR28/oGR30/OGR31,  
oGR29/oGR30/OGR31, oGR25/oGR16, oGR25/oGR18,  
oGR26/oGR16, oGR26/oGR18, oGR27/oGR16, oGR27/oGR18,  
oGR28/oGR16, oGR28/oGR18, oGR29/oGR16, oGR29/oGR18,  
20 oGR39/oGR20, oGR40/oGR20, oGR41/oGR20, oGR42/oGR20,  
oGR43/oGR30/OGR31, oGR44/oGR30/OGR31,  
oGR45/oGR30/OGR31, oGR43/oGR16, oGR43/oGR18,  
oGR44/oGR16, oGR44/oGR18, oGR45/oGR16, oGR45/oGR18  
oGR46/oGR20, oGR47/oGR20, oGR48/oGR20, oGR49/oGR20,  
25 oGR50/oGR30/OGR31, oGR51/oGR30/OGR31,  
oGR52/oGR30/OGR31, oGR50/oGR16, oGR50/oGR18,  
oGR51/oGR16, oGR51/oGR18, oGR52/oGR16, oGR52/oGR18,  
oGR53/oGR20, oGR54/oGR20, oGR55/oGR20, oGR56/oGR20,  
oGR57/oGR30/OGR31, oGR58/oGR30/OGR31,  
30 oGR59/oGR30/OGR31, oGR57/oGR16, oGR57/oGR18,  
oGR58/oGR16, oGR58/oGR18, oGR59/oGR16, oGR59/oGR18

d) 3' and 5' RACE experiments

WO 02/42323

PCT/EP01/13604

- 35 -

To clone the full length cDNA encoding for the fluorescent proteins of the Polythoa species and the Discosoma species, 3' and 5' RACE experiments were performed. To facilitate these experiments additional  
5 cDNA was prepared. Starting from the RNA isolations as described above, new first strand cDNA synthesis was performed using the SMART PCR cDNA Synthesis Kit (Cat. NO. K1052-1; Clontech). 3' RACE PCR, was performed according to the manufacturers instructions of the  
10 SMART PCR cDNA Synthesis Kit. The 5' RACE ends of the cDNA fragments were amplified using a step-out RACE strategy (Matz, M. et al. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res. 27, 1558-1560 (1990)), or according  
15 to the manufacturers instructions of the SMART PCR cDNA Synthesis Kit.

The 3' ends of the Polythoa species were amplified in primary PCR reactions with the primer combinations oGR1-oGR20 and oGR2-oGR20. A sample of  
20 the primary PCR reaction was used as a template in nested PCR reactions using primer combinations oGR2-oGR20 and oGR3-oGR20 respectively

The 3' ends of the Discosoma species were amplified in primary PCR reactions with the specific  
25 primer combination oGR39/oGR20 after which a nested PCR was performed with primer combinations oGR40/oGR20 or oGR41/oGR20 or oGR42/oGR20. Primary PCR with primers combination oGR41/oGR20 was nested with oGR42/oGR20, and primary PCR reaction with primer  
30 combination oGR47/oGR20 was nested with primer combination oGR49/oGR20. Finally PCR reaction with primer combination oGR41/oGR20 was nested with oGR42/oGR20



WO 02/42323

PCT/EP01/13604

- 36 -

The primary PCR conditions were: 1' at 94°C, 30 PCR cycles (30" at 94°C, 1' at 55°C and 5' at 68°C) followed by 5' at 68°C

The PCR conditions of this nested PCR were as followed: 1' at 94°C followed by 35 cycles (30" at 94°C, 1' at 55°C and 5' at 72°C) and 5' at 72°C.

The 5' ends of the Polythoa species were amplified in primary PCRs with the specific 5' RACE primers combinations: oGR16/oGR28, oGR16/oGR25, oGR16/oGR26, oGR16/oGR27, oGR16/oGR28 and oGR16/oGR29. The following PCR conditions were used: 1' at 94°C, 20 PCR cycles (30" at 94°C, 1'30" at 72°C (-0.2°C/cycle)), 20 PCR cycles (30" at 94°C and 1'30" at 68°C) followed by 5' at 68°C.

15

The 5' ends encoding for the Discosoma species fluorescent proteins were amplified according to the Step-Out PCR protocol as mentioned above. Primary PCRs with 5' RACE primers combinations oGR10/oGR30/oGR31 and nested with primers combinations oGR11/oGR30/oGR31 was performed.

Other primary PCR/ nested PCR combinations were: oGR11/oGR30/oGR31, nested with oGR12/oGR30/oGR31, oGR12/oGR30/oGR31, nested with oGR13/oGR30/oGR31, oGR13/oGR30/oGR31, nested with oGR14/oGR30/oGR31, oGR43/oGR30/oGR31, nested with oGR44/oGR31 or oGR45/oGR31, oGR44/oGR30/oGR31, nested with oGR45/oGR31, oGR50/oGR30/oGR31, nested with oGR51/oGR31 or oGR52/oGR31, oGR51/oGR30/oGR31, nested with oGR52/oGR31, oGR52/oGR30/oGR31 oGR59/oGR30/oGR31

30

WO 02/42323

PCT/EP01/13604

- 37 -

The primary and nested PCR conditions were: 1' at 94°C, 35 cycles of PCR (30" at 94°C, 1' at 55°C and 2' at 72°C) followed by 5' at 72°C.

The 5' ends of the Discosoma species were also

5 amplified using specific 5' RACE primers combinations  
oGR43/oGR16, oGR43/oGR18, oGR44/oGR16, oGR44/oGR18,  
oGR45/oGR16, oGR45/oGR18, oGR50/oGR16, oGR50/oGR18,  
oGR51/oGR16, oGR51/oGR18, oGR52/oGR16, oGR52/oGR18 and  
oGR59/oGR16, oGR59/oGR18.

10 The PCR conditions were an initial denaturation of 1' at 94°C, followed by 20 cycles of touch down PCR (30" at 94°C, 1' at 72°C (-0.2°C/cycle)), followed by 20 cycles of PCR (30" at 94°C and 1' at 68°C) and 5' at 68°C.

15

All the resulting PCR products of the 3' and 5' RACE  
PCRs were analyzed on agarose gel and the appropriate  
DNA bands of interest were isolated and cloned into  
the pCR-XL-TOPO vector (Cat. NO. K4700-20; Invitrogen)  
20 and further analyzed by sequence analysis.

Primers oGR20, oGR16, oGR18, oGR30, oGR31 were  
provided by the manufacturers and encode for :

oGR20: GTAATACGACTCACTATAGGGCCGAGTCGACCGTTTTTTTTTTTTTT

25

oGR16 AAGCAGTGGTATCAACGCAGAGT

oGR18: AAGCAGTGGTAACAACGCAGAGT

oGR30: GTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT

oGR31: GTAATACGACTCACTATAGGGC

30

e) Cloning of full size cDNA encoding for  
fluorescent proteins from Anthozoa species.

WO 02/42323

PCT/EP01/13604

- 38 -

All cloning experiments were performed using standard protocols as provided by the manufacturers or as described by Ausubel et al. in Current Protocols in Molecular biology, *ibid*. Isolation of full length  
5 cDNA's was also performed using the Titan One tube RT PCR System (Boeringer Mannheim) The reactions were performed according to the manufacturers instructions.

10 i) Cloning of full size Polythoa 1 GFP cDNA

PCR was performed using specific primer combinations oGR32/oGR34, oGR32/oGR35, oGR33/oGR34 and oGR33/oGR35, and other primer combinations as described above. The resulting fragments were isolated  
15 and cloned in appropriate vectors, mainly the pCR-XL-TOPO vector.

The resulting plasmid was designated pGR22 (using primer combination oGR33:  
20 CTTGGTGATTTGGGAGAAGGCAGATCGAG and oGR34: CGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG).  
Polythoa 1 GFP cDNA was amplified by PCR using plasmid DNA pGR22 as template and the primers: oGR68: CTGGAATTCTATTACTTTGAGTCTACCATCATGAGTGCAATT and oGR72:  
25 CGTATCTCGAGCGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG. The resulting PCR products were analyzed by agarose gel electrophoresis and the DNA of interest was isolated and cloned into the pCR-XL-TOPO vector. The resulting plasmid was designated pGR26.

30

ii) Cloning of full size Polythoa 2 GFP cDNA:

To isolate the full size cDNA clone of the Polythoa species (here designated Polythoa 2), the

WO 02/42323

PCT/EP01/13604

- 39 -

Titan One Tube RT-PCR System (Cat. NO. 1888382, Boehringer Mannheim) was used. The reactions were performed according to the manufacturers procedure, using specific primers oGR32 till oGR38. More particularly the following primer combinations were successful:

oGR32/oGR34, oGR32/oGR35, oGR33/oGR34, oGR33/oGR35, oGR36/oGR37 and oGR36/oGR38.

10 oGR32: ACCTTGTTGATTTGGGAGAAGGCAGATCGAGAG;  
oGR33: CTTGGTGATTTGGGAGAAGGCAGATCGAG;  
oGR34: CGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG;  
oGR35: GAGAACTTCTTTTTCACTTTGTTGTCGTCTTG;  
oGR36: GACACTGGTGATTTGGGAGAAGGCAGATC;  
15 oGR37: ATTGCGAGCCACGGCAACTTCATACAGC;  
oGR38: GCCATAATCTGAAGAGGAGAATTGCGAGCCAC).

The resulting PCR products were analyzed by agarose gel electrophoresis and the DNA of interest was isolated and cloned into the pCR-XL-TOPO vector. The resulting plasmids were designated pGR1 (using primers combination oGR32/oGR34) and pGR8 (using primers combination oGR36/oGR38)

25 iii) Cloning of full size Discosoma 1 GFP cDNA

As in the previous experiments, specific primers were designed based upon the available sequence information resulting from earlier PCR reactions and 3' and 5' RACE PCR experiments. The isolation of a full length cDNA is analogous as described above.

iv) Cloning of full size Discosoma 2 GFP cDNA

WO 02/42323

PCT/EP01/13604

- 40 -

As in the previous experiments, specific primers were designed based upon the available sequence information resulting from earlier PCR reactions and 3' and 5' RACE PCR experiments. The isolation of a full length cDNA is analogous as described above.

**2) Cloning of new fluorescent proteins cDNA in expression vectors**

- 10 a) Cloning of Polytho2 GFP cDNA in prokaryotic expression vector:

Polythoa 2 GFP cDNA was amplified by PCR using plasmid DNA pGR1 as template and the primers:

15 oGR69: CTGGAATTCTCTACCGTCATGAGTGCAATTAAACAGTCA and  
oGR70: CGTATCTCGAGATTGCGAGCCACGGCAACTTCATACAGC.  
or by using plasmid DNA pGR8 as template and the primers oGR68:  
CTGGAATTCTATTACTTTGAGTCTACCATCATGAGTGCAATT and oGR72:  
20 CGTATCTCGAGCGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG.

The PCR product was purified and digested with the restriction enzymes EcoRI and XhoI and cloned in EcoRI/XhoI cloning sites of the expression vector pET32A (Cat. NO. 69015-3; Novagen), the resulting  
25 vectors were designated pGR3, and pGR7 respectively. The resulting expression in *E.coli* resulted in visual observation of the fluorescent protein, without induction or UV treatment indicating high expression  
30 levels or a fluorescent protein with a high emission amplitude.

- b) Cloning of Polytho2 in eukaryotic expression vector:

WO 02/42323

PCT/EP01/13604

- 41 -

Polythoa 2 cDNA was amplified by PCR using plasmid DNA pGR8 as template, and the primers combinations oGR69/oGR70 or oGR69/oGR71:

oGR69:CTGGAATTCTCTACCGTCATGAGTGCAATTAAACCAGTCA oGR70:

5 CGTATCTCGAGATTGCGAGCCACGGCAACTTCATACAGC.

oGR71: CGTATCTCGAGGCCATAATCTGAAGAGGAGAATTGCGAGCCAC

The PCR product was purified and digested with the restriction enzymes EcoRI and XhoI and cloned in EcoRI/XhoI cloning sites of the expression vector

10 pCDNA3 (Invitrogen), the resulting vectors were designated pGR4 and pGR5 respectively.

c) Cloning of Polytho2 in C. elegans expression vector:

15

Polythoa 2 cDNA was amplified by PCR using plasmid DNA pGR1 as template, and the primers:

oGR74: CGTCGGCGCGCCACCACCATGAGTGCAATTAAGCCAGTTATGAA and oGR72:

20 CGTATCTCGAGCGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG.

The PCR product was purified and digested with the restriction enzymes EcoRI and XhoI and cloned in EcoRI/XhoI cloning sites of the expression vector pDW2700, the resulting vector was designated pGR6 .

25

d) Cloning of Polythoa 1 GFP cDNA in prokaryotic expression vector:

An 752bp EcoRI/XhoI fragment of pGR26 was isolated, purified and ligated into the EcoRI/XhoI cloning sites of the expression vector pCDNA3 (Invitrogen). The resulting vector was designated pGR24. The resulting expression in COSI cells resulted in visual observation of the flurescent protein, after UV treatment.

30

WO 02/42323

PCT/EP01/13604

- 42 -

e) Cloning of Polythoa 1 GFP cDNA in eukaryotic expression vector:

An 752bp EcoRI/XhoI fragment of pGR26 was isolated, purified and ligated into the EcoRI/XhoI cloning sites of the expression vector pET32A (Cat. NO. 69015-3; Novagen). The resulting vector was designated pGR25.

**3) Expression of new fluorescent proteins.**

10 a) expression of Polythoa 2 GFP in E. coli

Expression in E.coli was performed according the instructions of the pET32A provider (Novagen). Both the plasmids pGR3 and pGR7 resulted in clear expression in E. coli.

b) expression of Polythoa 2 GFP in Mammalian cells

20 COS I :African green monkey kidney cell line, standardly cultured in DMEM with Na-pyruvate supplemented with 10% fetal calf serum (Life Technologies) and antibiotics (Pen/Strep; Life Technologies), was transfected with pGR4.

25 The cells were seeded at a concentration of  $1.5 \times 10^4$  cells/well in 24-well plate and  $7.5 \times 10^4$  cells/well in 1 well coverglass and transduced the day after with Lipofectamine Plus reagent (GibcoBRL 10964-013), according to the manufacturers instructions.

30 The following day, the cells were washed twice with PBS (Life Technologies), and complete medium (1ml for 24-well, 3ml for coverglass) was added. Fluorescence of the cells after 24 hours was observed by using UV-light of the microscope with filter 450-490

WO 02/42323

PCT/EP01/13604

- 43 -

(FT510 ;LP520). Both the plasmids pGR4 and pGR5 resulted in clear expression in Cos I cells

c) Expression of Polythoa 2 GFP in C. elegans.

5

C. elegans wild-type strain was transformed with pGR6 using microinjection techniques known in the art, and described in Methods in Cell Biology, Vol48: C. elegans, Modern biological analysis off an organism, 10 ed. by Epstein and Shakes. pGR6 resulted in clear expression of GFP in C.elegans.

#### 4) Mutant fluorescent proteins

15 To further improve the characteristics of the isolated mutant fluorescent proteins, mutagenesis experiments were performed. Improvements of the fluorescent proteins can be of different nature, such as improved absorption spectra, improved emissions spectra, 20 enhancement of the chromophore, etc.

Site directed mutagenesis can be performed as described in Current protocols in Molecular Biology, ed by Ausubel et al, or as provided in the by the 25 QuickChange Site-Directed Mutagenesis Kit (Stratagene, CA, USA) or by related methods as known in the art. Random mutagenesis, and more particularly molecular evolution techniques can be performed as described by Kunchner and Arnold, 1997, tibtech 15:523-530; 30 Stemmer, 1994, Nature 370:389-391; Stemmer, 1994, Proc. Natl. Acad. Sci. USA 91:10747-10751, or by related methods as known in the art.



**PCT/EP01/13604**

During the cloning of the full length cDNA's in the vectors using PCR technology, mutant fluorescent proteins were created. More particularly the plasmids pGR3, pGR4, pGR5, and pGR8 contain a mutant Polythoa 2 N41D GFP, while plasmid pGR7 expresses a Polythoa 2 Q136R GFP mutant and pGR10 is expresses a I106T mutant. The expression experiments described above clearly indicate that mutations introduced in the newly isolated fluorescent proteins, conserves the basic fluorescence property of the protein..

The mutation Q136R in pGR7 was remutagenised towards the natural occurring Polythoa 2 FP using the QuikChange Site Directed Mutagenesis Kit and the primers

oGR90: GACCCAACGGCCCAATTATGCAGAAGAAGACCCTGAAATGGGAG  
and oGR91:

CTCCCATTTTCAGGGTCTTCTTCTGCATAATTGGGCCGTTGGGGTC. The resulting vector was designated pGR13

25                   a) Cloning of a Polythoa 2-discosoma 1 hybrid GFP  
cDNA in prokaryotic expression vector:

The 3' end of the *Discosoma* species was amplified in primary PCR reaction with the specific primer combination oGR39/oGR20 as mentioned above (see 1)d). The resulting PCR products were analyzed on agarose gel and the appropriate DNA band of interest was isolated and cloned into the pCR-XL-TOPO vector (Cat.

WO 02/42323

PCT/EP01/13604

- 45 -

NO. K4700-20; Invitrogen). The resulting vector was designated pGR17. Plasmid DNA of pGR17 was digested with the restriction enzymes EcoRV and StuI and analyzed on agarose gel. The appropriate band of 525bp  
5 was isolated and cloned into the 3736 bp EcoRV fragment of pGR1. The resulting vector was designated pGR14. The resulting expression in E.coli resulted in visual observation of the fluorescent protein, after UV treatment. An 124bp EcoRI-HindIII fragment of  
10 pCDNA3.1/hisA ( Invitrogen) was isolated, purified and ligated into the 4212bp EcoRI-HindIII fragment of pGR14. The resulting vector was designated pGR15. The resulting expression in E.coli resulted in visual observation of the fluorescent protein, after UV  
15 treatment.

b) Cloning of a Polythoa 2-Discosoma 1 hybrid GFP cDNA in eukaryotic expression vector:

20 Polythoa 2 - Discosoma 1 hybrid cDNA was amplified by PCR using plasmid DNA pGR14 as a template and the primers: oGR69:  
CTGGAATTCTCTACCGTCATGAGTGCAATTAAACCAGTCA and oGR96:  
CGTACCTCGAGCCTTTACTTGGTCAGCCGGCTCGGCAGCTTGG. The PCR  
25 product was purified and cloned in the cloning vector pCR-XL-TOPO. ). The resulting vector was designated pGR19. The 705 bp EcoRI/XhoI fragment of pGR19 was isolated, purified and cloned in EcoRI/XhoI cloning sites of the expression vector pCDNA3 (Invitrogen)).  
30 The resulting vector was designated pGR18. The resulting expression in COSI cells resulted in visual observation of the fluorescent protein, after UV treatment.

WO 02/42323

PCT/EP01/13604

- 46 -

c) Cloning of a Polythoa 2-discosoma 1 hybrid GFP cDNA in C. elegans expression vector:

Polythoa 2 - Discosoma 1 hybrid cDNA was amplified by PCR using plasmid DNA pGR14 as template, and the primer combination oGR75:

CGTCGGCGCGCCATCATGAGTGCAATTAAACCAGTCATGAAGAT and oGR96: CGTACCTCGAGCCTTTACTTGGTCAGCCGGCTCGGCAGCTTGG.

The PCR product was purified and cloned in the cloning vector pCR-XL-TOPO. The resulting vector was designated pGR21. The 700 bp AscI/XhoI fragment of pGR21 was isolated, purified and cloned in the AscI/XhoI cloning site of the expression vector pDW2700. The resulting vector was designated pGR20. The resulting expression in C. elegans resulted in visual observation of the fluorescent protein, after UV treatment.

6) Establishing the excitation and emission spectra of the new green fluorescent proteins

Isolation of protein from Polythoa 2 GFP, Polythoa2 N41D GFP and Polythoa 2-discosoma 2 fusion GFP.

The fluorescent proteins were expressed in E. coli from vector pGR3 (N41D), pGR7(Q136R), pGR13 (back-mutation, natural occurring Polythoa 2 FP), pGR15 (Polythoa-discosoma hybrid protein) and purified using the BugBuster Protein Extraction Reagent (Cat. NO.: 70584-3; Novagen) and the His-Bind Buffer Kit (Cat. NO.: 69755-3; Novagen) according to the manufacturers instructions.

The excitation and emission spectra of the samples were then determined. All samples were excited at

WO 02/42323

PCT/EP01/13604

- 47 -

490nm. The spectra were corrected for  
photomultiplier response and monochromator  
transmittance, transformed to wave number and  
integrated. All experiments were performed in a Amico  
5 Bowman Series 2 Luminescence spectrometer (SLM-Amico  
Spectronic instruments)

1) Synthetic Polythoa 2 Fluorescent protein with  
optimal codon usage for C. elegans.

10

To enhance the performance of the fluorescent proteins  
in organisms other than the Cnidaria species from  
which these fluorescent proteins were isolated, the  
codon usage was altered. Although the genetic code is  
15 considered to be universal, every organism has its  
preferred codon usage, which is related to the  
presence and the expression of tRNA genes, and hence  
is involved in post-transcriptional expression  
regulation. Such optimal codon usage has been  
20 determined for many organisms, including *E.coli* (Dong  
et al., 1996, J. Mol. Biol. 260:649-663), *B. subtilis*  
(Kanaya et al., 1999, Gene 238:143-155), *Drosophila*  
(Moriyama et al., 1997, J. Mol. Evol. 45:514-523)  
*Saccharomyces* (Percudani et al., 1997, J. Mol  
25 Biol. 268:322-330), *C. elegans* (Stenico, et al., 1994,  
NAR 22:2437-2446). An overview of codon usage in these  
and other organisms can be found in Duret et al.,  
1999, Proc. Natl. Acad. Sci. U.S.A. 96: 4482-4487 and  
in Ikemura, 1985, Mol. Biol. Evol. 2:13-43.

30

The synthetic 922 bp gene was amplified using  
herculase-polymerase at Entechelon, Germany and was  
delivered as a ligation product. This product was  
cloned into pCR-XL-TOPO (pGR16). The 888bp FseI-NheI

WO 02/42323

PCT/EP01/13604

- 48 -

fragment of pGR16 was cloned into the FseI/NheI  
cloning sites of the expression vector pDW2721 and the  
resulting vector was designated pGR10. This plasmid  
was injected in *C. elegans*, and clearly resulted in  
5 fluorescence

## 2) Synthetic introns in worm construct

In many organisms, such as in *C.elegans*, the  
10 introduction of synthetic introns results in  
enhancements of expression levels (Fire et al. , 1990,  
Gene 93:189-98, end references therein).

An example is hereby included of a *Polythoa* 2  
fluorescent protein improved for optimal codon usage  
15 for *C. elegans* and with synthetic *C.elegans* introns.  
Such synthetic genes can be made easily by a person  
skilled in the art, or be ordered by companies such as  
Entelechon, Rgensburg, Germany.

## 20 Fusion proteins

GFP proteins have been used for many purposes in  
biological research. The main use nevertheless has  
been the expression pattern of proteins in cells and  
25 multi-cellular organisms, and the subcellular  
localization or trafficking of proteins. To determine  
the expression pattern of a protein using GFP's it  
suffices in principle to make a fusion between the  
promoter of the gene of interest and the GFP. Upon  
30 introducing a vector with this promoter GFP fusion  
into the studied cell or organism, the expression  
induced by the promoter can easily be monitored by  
following the GFP expression. To monitor the  
subcellular expression of a protein, it suffices to

WO 02/42323

PCT/EP01/13604

- 49 -

make a fusion between the protein of interest and the GFP protein. this can be done at the N-terminal site or at the C-terminal site of the GFP protein, and even internal fusions are possible . Plasmids pGR3, pGR7  
5 and pGR13 are good examples of such fusion proteins as they contain a 109 thiroredoxin Aminoacid fragment in fusion with the Polythoa 2 GFP. This fusion protein shows clear fluorescence.

WO 02/42323

PCT/EP01/13604

- 50 -

TABLE 1

primers	5'—3'
oGR1	CACCACATGGAAGGAWRYKTNRAYGG
oGR2	ACCACATGGAAGGATGCKTNRAYGGNCA
5 oGR3	AATTTGTGATCAAGGGCRARGGNRWNGG
oGR4	GTGATCAAAGGTGGACCNNTNCCNTT
oGR5	GACATATTGTCAACAGAGTTYMANTAYG
oGR6	CATATTGTCAACAGAGTTYMANTAYGG
oGR7	ATCCTGACGACATACCAGAYTAYHWNAA
10 oGR8	GACTATTTCAAGCAGTCGTYCCNGMNNGG
oGR9	CATGGGAAAGGTCCTTGCAITWYGARGA
oGR10	GGTGACATCTCCTTTTCARNAYNCC
oGR11	CATATTCTCAGTGGANGSNTCCCA
oGR12	CACAGGTCCATCGSNAGGRAARTT
15 oGR13	CCATCGGCAGGAAARTTNANNCC
oGR14	TGAATACCCTGTTTCCRTANTKRAA
oGR16	AAGCAGTGGTATCAACGCAGAGT
oGR18	AAGCAGTGGTAACAACGCAGAGT
oGR20	GTAATACGACTCACTATAGGGCCGAGTCGACCGTTTTTTTTTTTTT
20 oGR21	AAAGGCGTGCCCTTCTTTTCGCTTTTGA
oGR22	TGTCAACAGCATTCCAGTATGGCAACAGGGTA
oGR23	TGAAGAGGGCGTTTGACCAACAAAGAGTG
oGR24	AAAGGGGAGAAGCTTGACCCCAACGGCC
oGR25	TTGAAAGCAGTCTGGTTGGCCTTTCTTGA
25 oGR26	TGTGGTGCAAACGCCCTCTTCATATTTGAA
oGR27	CCCTGTTGCCATACTGGAATGCTGTTGAC
oGR28	AAGGAAGGGGCAGCCTTTAGTGACTGTAAG
oGR29	CTTGCCCTTGTCCTCTCCCCTGATCGTGA
oGR30	GTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT
30 oGR31	GTAATACGACTCACTATAGGGC
oGR32	ACCTTGGTGATTTGGGAGAAGGCAGATCGAGAG
oGR33	CTTGGTGATTTGGGAGAAGGCAGATCGAG
oGR34	CGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG
oGR35	GAGAAACTTCTTTTTCACTTTGTGTGCTCTTG
35 oGR36	GACACTGGTGATTTGGGAGAAGGCAGATC
oGR37	ATTGCGAGCCACGGCAACTTCATACAGC
oGR38	GCCATAATCTGAAGAGGAGAATTGCGAGCCAC
oGR39	GGAGAAGGAGAAGGAAAACCATACGAGGG
oGR40	CCAGTACGGCAACAGGGCATTACCAAAT
40 oGR41	GGGAAAGAACCATGAATTTTGAAGACGGG
oGR42	CCCCCATTTGGCCAGTTATGCAGAAGAA
oGR43	GCCAATGGGGGGAAAGTTTCGCACCATCAA
oGR44	CGCCCCGTCTTCAAAATTCATGGTTCTT
oGR45	CCTGTTGCCGTACTGGAACGCTGTTGTCA
45 oGR46	TGGGAAGTCTTATGATGGCACCAATACCG
oGR47	TTCAGGTAACCAAGGGTGGACCTCTGCCA
oGR48	TGTCAGGCATCCCGAAGACATCGCTGATT
oGR49	CATGCACTTTGAAGACGGTGGCGTGTGT

WO 02/42323

PCT/EP01/13604

- 51 -

	oGR50	TCATTGGTGATACAACACACGCCACCGTC
	oGR51	CATGACCCTTTCCCATGTAAATCCTTCGGGA
	oGR52	TTGTGGTGACAAAATAGGCCAAGCAAATGGC
	oGR53	GAAATAAAAGGCGACGGTCACGGGAAGCC
5	oGR54	CATGGTAACCAAGGGTGGACCCCTGCCAT
	oGR55	AAANCTGTCGTTTCCCGAGGGATTACAT
	oGR56	TGGCGTGATTTGCAGCNCCAATGATATCA
	oGR57	CGCCACCGNCTTCAAAGTGCATGACCCTT
	oGR58	ANCGGCTATGTCTTCAGGGTGCTTGACAA
10	oGR59	GGTCCACCCTTGTTACCATGAGCTTGACGTT
	oGR68	CTGGAATTCTATTACTTTGAGTCTACCATCATGAGTGCAATT
	oGR69	CTGGAATTCTCTACCGTCATGAGTGCAATTAAACCAGTCA
	oGR70	CGTATCTCGAGATTGCGAGCCACGGCAACTTCATACAGC
	oGR71	CGTATCTCGAGGCCATAATCTGAAGAGGAGAATTGCGAGCCAC
15	oGR72	CGTATCTCGAGCGTCTTGGCTTTTCGTTAAGCCTTTACTGGGG
	oGR74	CGTCGGCGCGCCACCACCATGAGTGCAATTAAGCCAGTTATGAA
	oGR75	CGTCGGCGCGCCATCATGAGTGCAATTAACCAGTCATGAAGAT
	oGR90	GACCCCAACGGCCCAATTATGCAGAAGAAGACCCTGAAATGGGAG
	oGR91	CTCCCATTTACAGGGTCTTCTTCTGCATAATTGGGCCGTTGGGGTC
20	oGR96	CGTACCTCGAGCCTTTACTTGGTCAGCCGGCTCGGCAGCTTGG
	oGR97	CGTACCTCGAGGATGGATCCTTTACTTGGTCAGCCG
25		



WO 02/42323

PCT/EP01/13604

- 52 -

Table 2 Primer combinations

	oGR1	oGR10	
	oGR1	oGR11	
	oGR1	oGR12	
5	oGR1	oGR13	
	oGR1	oGR14	
	oGR1	oGR20	
	oGR10	oGR30	oGR31
	oGR11	oGR30	oGR31
10	oGR12	oGR30	oGR31
	oGR13	oGR30	oGR31
	oGR14	oGR30	oGR31
	oGR16	oGR25	
	oGR16	oGR26	
15	oGR16	oGR27	
	oGR16	oGR28	
	oGR16	oGR29	
	oGR2	oGR10	
	oGR2	oGR11	
20	oGR2	oGR12	
	oGR2	oGR13	
	oGR2	oGR14	
	oGR2	oGR20	
	oGR21	oGR20	
25	oGR22	oGR20	
	oGR23	oGR20	
	oGR24	oGR20	
	oGR25	oGR16	
	oGR25	oGR18	
30	oGR25	oGR30	oGR31
	oGR26	oGR16	
	oGR26	oGR18	
	oGR26	oGR30	oGR31
	oGR27	oGR16	
35	oGR27	oGR18	
	oGR27	oGR30	oGR31
	oGR28	oGR16	
	oGR28	oGR18	
	oGR28	oGR30	oGR31
40	oGR29	oGR16	
	oGR29	oGR18	
	oGR29	oGR30	oGR31
	oGR3	oGR10	
	oGR3	oGR11	
45	oGR3	oGR12	

WO 02/42323

PCT/EP01/13604

- 53 -

	oGR3	oGR13	
	oGR3	oGR14	
	oGR3	oGR20	
	oGR32	oGR33	
5	oGR32	oGR34	
	oGR32	oGR35	
	oGR33	oGR34	
	oGR33	oGR35	
	oGR34	oGR35	
10	oGR36	oGR37	
	oGR36	oGR38	
	oGR39	oGR20	
	oGR4	oGR10	
	oGR4	oGR11	
15	oGR4	oGR12	
	oGR4	oGR13	
	oGR4	oGR14	
	oGR40	oGR20	
	oGR41	oGR20	
20	oGR42	oGR20	
	oGR43	oGR16	
	oGR43	oGR18	
	oGR43	oGR30	oGR31
	oGR44	oGR16	
25	oGR44	oGR18	
	oGR44	oGR30	oGR31
	oGR44	oGR31	
	oGR45	oGR16	
	oGR45	oGR18	
30	oGR45	oGR30	oGR31
	oGR45	oGR31	
	oGR46	oGR20	
	oGR47	oGR20	
	oGR48	oGR20	
35	oGR49	oGR20	
	oGR5	oGR10	
	oGR5	oGR11	
	oGR5	oGR12	
	oGR5	oGR13	
40	oGR5	oGR14	
	oGR50	oGR16	
	oGR50	oGR18	
	oGR50	oGR30	oGR31
	oGR51	oGR16	

WO 02/42323

PCT/EP01/13604

- 54 -

	oGR51	oGR18	
	oGR51	oGR30	oGR31
	oGR51	oGR31	
	oGR52	oGR16	
5	oGR52	oGR18	
	oGR52	oGR30	oGR31
	oGR52	oGR31	
	oGR53	oGR20	
	oGR54	oGR20	
10	oGR55	oGR20	
	oGR56	oGR20	
	oGR57	oGR16	
	oGR57	oGR18	
	oGR57	oGR30	oGR31
15	oGR58	oGR16	
	oGR58	oGR18	
	oGR58	oGR30	oGR31
	oGR59	oGR16	
	oGR59	oGR18	
20	oGR59	oGR30	oGR31
	oGR6	oGR10	
	oGR6	oGR11	
	oGR6	oGR12	
	oGR6	oGR13	
25	oGR68	oGR72	
	oGR69	oGR70	
	oGR69	oGR71	
	oGR69	oGR96	
	oGR69	oGR97	
30	oGR7	oGR10	
	oGR7	oGR11	
	oGR7	oGR12	
	oGR7	oGR13	
	oGR72	oGR74	
35	oGR75	oGR96	
	oGR75	oGR97	
	oGR8	oGR10	
	oGR8	oGR11	
	oGR8	oGR12	
40	oGR8	oGR13	
	oGR9	oGR10	
	oGR9	oGR11	
	oGR9	oGR12	
	oGR9	oGR13	

WO 02/42323

PCT/EP01/13604

- 55 -

**CLAIMS:**

1. An isolated nucleic acid molecule encoding a fluorescent protein comprising an amino acid sequence  
5 illustrated in any of the polypeptide sequences of figures, 3(a) to 3(d) or functional equivalents, fragments or variants thereof.
2. An isolated nucleic acid molecule encoding a  
10 protein capable of emitting fluorescence upon irradiation by incident light, wherein said maximal absorbance of said incident light is in the range 440-480 nm, and maximal fluorescence emission is in the range 470-510 nm.
3. An isolated nucleic acid molecule according  
15 to claim 2, wherein said molecule encodes a protein having an amino acid sequence as depicted in any of the polypeptide sequences of Figures 3(a) to 3(d).
4. An isolated nucleic acid molecule according  
20 to claim 1 wherein said fluorescent protein comprises an amino acid sequence having combined polypeptide sequences from at least 2 of the polypeptide sequences depicted in Figures 3(a) to 3(d).
5. An isolated nucleic acid molecule according  
25 to claim 4 wherein said protein comprises a Polythoa 2-Discosoma 1 hybrid having the sequence illustrated in Figure 7.
6. An isolated nucleic acid molecule encoding a  
30 fusion protein comprising an amino acid sequence

WO 02/42323

PCT/EP01/13604

- 56 -

depicted in any of Figures 3(a) to 3(d) together with a nucleotide sequence encoding a protein of interest.

7. An isolated nucleic acid molecule according to claim 6 wherein said fusion protein comprises the amino acid sequences depicted in Figures 4 and 5.

8. An isolated nucleic acid molecule according to claim 5 wherein said protein of interest is an antibody.

9. An isolated nucleic acid molecule according to any of claims 1 to 8, which is a DNA molecule.

10. An isolated nucleic acid molecule according to claim 9, wherein said DNA molecule is cDNA.

11. An isolated nucleic acid molecule according to any of claims 1 to 10, which is derived from an Anthozoa species.

12. An isolated nucleic acid molecule according to claim 11, wherein said Anthozoa species is any of a Polythoa or Discosoma species.

13. An isolated nucleic acid molecule according to any preceding claim, wherein said molecule comprises a nucleotide sequence which has at least 70, preferably at least 80, more preferably at least 90 and even more preferably at least 95% sequence identity to the nucleic acid sequences depicted in Figure 1.

WO 02/42323

PCT/EP01/13604

- 57 -

14. An isolated nucleic acid molecule according to any preceding claim, wherein said nucleic acid molecule comprises any of the nucleic acid sequences depicted in Figure 1.

5

15. An isolated nucleic acid molecule according to claim 13 comprising any of the nucleotide sequences depicted in Figure 2(a) or 2(b).

10 16. An antisense molecule capable of hybridising to a nucleic acid molecule according to any of claims 1 to 13, under conditions of high stringency.

15 17. An isolated fluorescent protein or functional equivalent, derivative or variant thereof encoded by a nucleic acid molecule according to any of claims 1 to 13.

20 18. An isolated fluorescent protein capable of emitting fluorescence upon irradiation by incident light wherein the maximal absorbance of said incident light is in the range 440-480 nm, and maximal fluorescence emission is in the range 470-510 nm.

25

19. An isolated fluorescent protein comprising an amino acid sequence which has at least 70, preferably at least 80, more preferably at least 90 and even more preferably at least 95% sequence identifying to the amino acid sequence depicted in  
30 Figures 3 to 8.

20. An isolated fluorescent protein comprising an amino acid sequence corresponding substantially the

WO 02/42323

PCT/EP01/13604

- 58 -

polypeptide sequences depicted in any of Figures 3 to 8.

21. An isolated fusion fluorescent protein  
5 comprising a fluorescent protein according to any of  
claims 16 to 20 together with the amino acid sequence  
of a protein or polypeptide of interest.

22. A fluorescently labelled antibody or a  
10 paratope thereof coupled to a fluorescent protein  
according to any of claims 16 to 20.

23. An expression vector comprising any of the  
nucleic acid molecules according to claims 1 to 15.  
15

24. An expression vector comprising any of the  
plasmid sequences depicted in Figures 9 to 14.

25. An expression vector comprising the  
20 sequences of any of plasmids pGR8 to pGR20.

26. A host cell transformed or transfected with  
an expression vector according to any of claims 23 to  
25.

27. A prokaryotic cell transformed or  
transfected with any of expression vectors pGR3, pGR7  
depicted in Figures 9 and 13 or pGR13.

28. A prokaryotic cell according to claim 25  
30 which is *E.coli*.

29. A eukaryotic cell transformed or  
transfected with an expression vector corresponding

WO 02/42323

PCT/EP01/13604

- 59 -

substantially to the plasmids designated pGR4 or PGR5  
in Figures 10 or 11.

30. A transgenic cell tissue or non-human  
5 organism comprising a transgene capable of expressing  
a fluorescent protein according to any of claims 17 to  
21 or an antibody according to claim 22.

31. A transgenic cell, tissue or non-human  
10 organism according to claim 30, wherein said transgene  
is included in an expression vector.

32. A transgenic cell, tissue or non-human  
15 organism according to claim 31, wherein said vector is  
one according to claim 23.

33. A transgenic cell, tissue or non-human  
organism wherein said non-human organism is C-elegans  
and said transgene substantially corresponds to a  
20 nucleotide sequence as depicted in Figure 12.

34. A fluorescent protein, or a functional  
equivalent, derivative or bioprecursor thereof,  
expressed by a cell, tissue or organism according to  
25 any of claims 27 to 33.

35. A process for producing the protein of any  
one of claims 17 to 21, comprising the steps of  
cultivating a cell tissue or organism according to any  
30 of claims 24 to 33 under conditions suitable for  
expression of the protein and optionally recovering  
the expressed protein.



WO 02/42323

PCT/EP01/13604

- 60 -

36. An oligonucleotide probe comprising at least about 10 nucleotides of a nucleotide sequence that is capable of selectively hybridising to a nucleic acid molecule according to any of claims 1 to 15.

37. A method for selecting cells capable of expressing a protein of interest, comprising introducing into said cells a vector comprising the nucleotide sequence of a fluorescent protein according to any of claims 17 to 22 operatively linked to a promoter or regulatory region of the protein of interest, cultivating the cell under conditions necessary for expressing the protein of interest and monitoring for any fluorescence following expression of said fluorescent protein.

38. A method for producing fluorescence resonance energy transfer comprising;  
providing a donor molecule comprising a fluorescent protein according to any of claims 17 to 21;  
providing an appropriate acceptor molecule for the fluorescent protein; and  
bringing the donor molecule and acceptor molecule into sufficiently close contact to allow fluorescent resonance energy transfer.

39. A method for producing fluorescence resonance energy transfer comprising;  
providing an acceptor molecule comprising a fluorescent protein according to any of claims 17 to 21;

WO 02/42323

PCT/EP01/13604

- 61 -

providing an appropriate donor molecule for the  
fluorescent protein; and

bringing the donor molecule and acceptor molecule  
into sufficiently close contact to allow fluorescence  
5 resonance energy transfer.

40. A microscopic nematode comprising a transgene  
capable of expressing a fluorescent protein according  
to any of claims 17 to 20.  
10

41. A nematode according to claim 40 which is  
*C. elegans*.

42. A fluorescent protein obtainable from the coral  
15 species Anthozoa.

43. A fluorescent protein according to claim 41 which  
is obtainable from Discosoma or Polythoa.

20 44. A fluorescent protein according to claim 42 or 43  
which is capable of emitting fluorescence upon  
irradiation by incident light wherein the maximal  
absorbance of said incident light is in the range 440-  
480 nm, and maximal fluorescence emission is in the  
25 range 470-510 nm.

45. A fluorescent protein according to claim 42 or 43  
comprising an amino acid sequence which has at least  
70, preferably at least 80, more preferably at least  
30 90 and even more preferably at least 95% sequence  
identifying to the amino acid sequence depicted in  
Figures 3 to 8

WO 02/42323

PCT/EP01/13604

CDNA fragment of polythoa 1 encoding for a fluorescent protein  
Start codon ATG and stop codon TAA are indicated.

```

1 acgcggggat tcaccttggg gatttgggag aaggcagatc gagagcaaga gtcagtgttaa
61 taacttactt tgagtctacc atcagtgagt caattaagcc agttatgaag gtagaattgg
121 tcatggaagg aaatgtgaac gggcacaaat tcacgattac aggagagggg caaggcaagc
181 cttacgaggg aactcacact ctaaaccctta cagtcacaaa aggcggggccc cttcctttcg
241 cttacgatat cttgtcarca gcattccagt acggcaacag ggtatttacc aaatacccag
301 aagatatacc ggactatttc aagcagacct ttccagaagg atattcgtgg gaaagaactt
361 tcaaatatga cgagggcctt tgcaccacaa aaagtgcac atgcctcaag aaaggcgaac
421 cggactgctt tcaatacaaa atttactttg aaggggaagaa ccttggccccc agcgggtccaa
481 ttatgcagaa gaagaccctg aaatgggagc catccactga gaggatgtac atggacgtgg
541 ataaagacgg tgcaaagggtg ctgaagggcg atgataatgc ggccctgttg cttgaaggag
601 gtggccatta tcgtttgtgac ttcaatagta ttacaaggc gaagaaaact gggctcttgc
661 cagcatatca ctggatagac caccgcattg agattttgag ccacgataaa gattacaaca
721 aggttacaat gcatgaattt gcgctgctc gtaattctcc ttttccgata atggcgcccc
781 agttaaaggct taacgaaaag ccaagacgac acaaaagtga aaaaagaagt tctcgtttac
841 ttttttctga aggcatttat cactaattag cttttgatag ttttgattca cggattcgtt
901 ccatgaattt cttagggact agctctagaa taaatgattg tgaacaaaaa actagttttc
961 atattttgag agatttttca cttcataaag acagactttt taaactcagt tgtagccaaa
1021 tacaataaag gaaagtgtat taagaattaa acaacttgtt tgtggaaaaa taataaaaac
1081 ggtcgactgc ggccctataa tgagtcgtat tac

```

(a)

CDNA fragment of polythoa 2 encoding for a fluorescent protein  
Start codon ATG and stop codon TAA are indicated.

```

1 acgcgggggac actggtgatt tgggagaagg cagatcgaga gcaagagtca gtgtaataac
61 ttacttttag tctaccgtca tgcagtgcaat taaaccagtc atgaagattg aattggtcat
121 ggaaggagag gtgaacgggc acaagttcac gatcacggga gagggacaag gcaagcctta
181 cgagggaaca cagactctaa accttacagt cactaaaggc gtgccccttc ctttcgcttt
241 cgatatcttg tcaacagcat tccagtagtg caacagggtg tttaccaa atccagatga
301 tataccggac tatttcaagc agacctttcc ggaaggatat tcgtgggaaa gaactttcaa
361 atatgaagag ggcgttttga ccacaaagag tgacataagc ctcaagaaag gcccaaccaga
421 ctgctttcaa tataaaatta actttaagg ggagaagctt gaccccaacg gcccaattat
481 gcagaagaag accctgaaat gggagccatc cactgagagg atgtacatgg acgtggataa
541 agacggtgca aagggtgctga agggcgatgt taatgcggcc ctggtgcttg aaggagggtg
601 ccattatcgt tgtgacttta acagtactta caaggcgaag aaaactgtgt ccttcccagc
661 atatcacttt gtggaccacc gcattgagat tttgagccac aatacggatt acagcaaggt
721 tacactgtat gaagttgccg tggctgcgaa ttctcctctt cagattatgg cgccccagta
781 aggccttaac gaaacgccaa tacgacaaca aagtgaaaaa caagtttttc gttatttttt
841 tctgaaagca tttatcacta attagctttt gatagttttg attcacggat tcatccgga
901 atttaataag gactagctct agtctagaat aaacgattgt gtaacaaaaa ctagctttca
961 taattttcgg gatttttcac ttcataaaga cagacttttt aaactcagtt gttagccaaat
1021 acaataaagg aaagcgtatt aagaattaa caaacttgtt gtcgaaaaaa aaaaaaacgg
1081 tcgattgcgg ccctatagtg agtcgtatta c

```

(b)

CDNA fragment of discosoma 1 encoding for a fluorescent protein  
start codon TAA are indicated.

```

1 caccacatgg aaggaagtgt ggacgggcaa aatttcgtga tcaactggaga aggagaagga
61 aaaccatacg agggaaacaca tgttatagac ctgcaagtcg ttgaaggcgg acctctgcgt
121 ttcgcttacg atatcttgac aacagcgttc cagtacggca acagggcatt caccaaatac
181 ccatcagata ttccctgacta ttccaagcag acttttcttc aagggtatag atgggaagaa
241 accatgcact ttgaagacgg tggcgtgtgt accgtcaata gcgacgtaag cctgaaagac
301 ggctgttttg agtataaaat tcgttttgat ggtgagaact ttcccccaa tggcccagtt
361 atgcagaaga agactgtgaa atgggagcca tccactgaga acatgtatga gcatgatggg
421 atgctgaagg gtgatgttag cagaactctg ttgcttgaag gagggtggcca ttaccaatgc
481 gactttaaaa ctatttacaa agcgaaggac agccagggaa tcaagatgcc agaatatcac
541 tttgtggacc accgcattga gattttgagc catgacaaag attacaagat ggtcaagggt

```

(c)

Fig 1

WO 02/42323

PCT/EP01/13604

```

601 tatgagattg ccgaagctca ctattccaag ctgccgagcc ggctgaccaa gtaaggcct
661 aaggaaaagc caacaagcca acaaggagga aaaaatacta gtgtttctag tacagttttt
721 taagccattt actaggaatt agtttttaat acttcagatc gtttcgggat ttgttagaga
781 ttagcttacg aaaactgata ctccctagagt ttctagtatt gtttttaagc catttactcg
841 gaattagttt ttgatacttt agatcgtttc ggaatttggt agagtttagc tttaaaaaaa
901 tactagactg

```

(c)  
(cont'd)

CDNA fragment of discosoma 2 encoding for a fluorescent protein

```

1 caccacatgg aaggaagtgt tgacggccac tactttgaaa ttaaaggcaa tggatatggg
61 aagtcttatg atggcaccaa taccgtaaag cttcaggtaa ccaagggtgg acctctgcca
121 tttgcttggc ctattttgtc accacaattt caatatggaa acaagatatt tgtcaggcat
181 ccgaagaca tcgctgatta taaaaagctg tcatttcccg aaggatttac atgggaaagg
241 gtcatgcact ttgaagacgg tggcgtgtgt tgtatcacca atgatatcag tttggaaggc
301 aactgtttca tctaccacat caatttcatt ggcttgaact ttccttccga tggacctgtg

```

(d)

Fig 1 (cont'd)

WO 02/42323

PCT/EP01/13604

DNA fragment encoding polythoa 2 with optimal codon usage for *C. elegans* as in plasmid pGR10.

(a)

```

1 atgtccgcta tcaagccagt catgaagatc gagctcgta tggagggaga ggtcaacgga
61 cacaagttca ccatcaccgg agagggacag ggaaagccat acgaggggaa ccagaccctc
121 aacctcaccg tcaccaaggg agtcccactc ccattcgctt tcgacatcct ctccaccgct
181 ttccagtagc gaaaccgtgt cttcaccaag taccagacg acatcccaga ctacttcaag
241 cagaccttcc cagagggata ctctggggag cgtaccttca agtacgagga gggagtctgc
301 accaccaagt ccgacatctc cctcaagaag ggacagccag actgcttcca gtacaagatc
361 aacttcaagg gagagaagct cgacccaaac ggaccaatca tgcagaagaa gacctcaag
421 tgggagccat ccaccgagcg tatgtacatg gacgtcgaca aggacggagc taaggtcttc
481 aagggagacg tcaacgctgc tctcctcctc gagggaggag gacactaccg ttgcgacttc
541 aactccacct acaaggctaa gaagaccgtc tccttcccag cttaccactt cgtcgaccac
601 cgtatcgaga tcctctccca caacaccgac tactccaagg tcacctcta cgaggtcgct
661 gtcgctcgta actccccact ccagatcatg gctccacag

```

DNA fragment encoding polythoa 2 with optimal codon usage for *C. elegans* further including introns. the introns are underlined. Furthermore the starting codon ATG is preceded by a 5' UTR containing an Kozak site.

(b)

```

1 tggetagcgt cgacgggtacc ggtagaaaa atgtccgcta tcaagccagt catgaagatc
61 gagctcgta tggagggaga ggtcaacgga cacaagtca ccatcaccgg agagggacag
121 ggaaagccat acgaggggaa ccagaccctc aacctcaccg tcaccaaggg agtcccactc
181 ccattcgctt tcgtaagttt aaacatatat atactaacta accctgatta tttaaatatt
241 caggacatcc tctccaccgc tttccagtac ggaaaccgtg tcttcacca gtaccagac
301 gacatcccag actacttcaa gcagaccttc ccagagggat actcctggga gcgtaccttc
361 aagtacgagg agggagtctg caccaccaag taagttttaa cagttcggta ctaactaacc
421 atacatattt aaattttcag gtccgacatc tccctcaaga agggacagcc agactgcttc
481 cagtacaaga tcaacttcaa gggagagaag ctcgacccaa acggaccaat catgcagaag
541 aagaccctca agtgggagcc atccaccgag cgtatgtaca tggacgtcga caaggacgga
601 gctaagggtcc tcaaggtaag tttaaaacttg gacttactaa ctaaccgatt atatttaaat
661 tttcagggag acgtcaacgc tgctctctc ctcgagggag gaggacacta ccgttgcgac
721 ttcaactcca cctacaaggc taagaagacc gtctccttcc cagcttacca cttcgtcgac
781 caccgtatcg agatcctctc ccacaacacc gactactcca aggtcaccct ctacgaggtc
841 gctgtcgctc gtaactcccc actccagatc atggctccac agtagggccg gccgagctcc
901 gcateggccg ctgtc

```

Fig 2

WO 02/42323

PCT/EP01/13604

## Protein sequence of polythoa 1

1 MSAIKPVMKV ELVMEGNVNG HKFTITGEGQ GKPYEGTHTL NLTVTKGGPL PFAYDILS~~TA~~  
61 FQYGNRVFTK YPEDIPDYFK QTFPEGYSWE RTFKYDEGLC TTKSDICLKK GEPDCFOYKI  
121 YFEGKNLGPS GPIMQKKTLK WEPSTERMYM DVDKDGAKVL KGDDNAALLL EGGGHYRCDF  
181 NSIYKAKKTG SLPAYHWIDH RIEILSHDKD YNKVTMHEFA AARNSPFPIM APQ\*

a

## Protein sequence of polythoa 2

1 MSAIKPVMKI ELVMEGEVNG HKFTITGEGQ GKPYEGTQTL NLTVTKGVPL PFAYDILSTA  
61 FQYGNRVFTK YPDDIPDYFK QTFPEGYSWE RTFKYEEGVC TTKSDISLKK GQPD~~CF~~OYKI  
121 NFKGEKLDPN GPIMQKKTLK WEPSTERMYM DVDKDGAKVL KGDVNAALLL EGGGHYRCDF  
181 NSTYKAKKTV SFPAYHFVDH RIEILSHNTD YSKVTLYEVA VARNSP~~LQ~~IM APQ\*

b

## Protein sequence of the N-terminal part of discosoma 1

1 HHMEGSVDGQ NFVITGEGEG KPYEGTHVID LQVVEGGPLR FAYDILT~~T~~AF QYGNRAFTKY  
61 PSDIPDYFKQ TFPQGYTWER TMHFEDGGVC TVNSDVSLKS GCFEYKIRFD GENFPPNGPV  
121 MQKKTIVKWE STENMYEHDG MLKGDVSR~~T~~L LLEGGGHYQC DFKTIYKAKD SQGIKMPEYH  
181 FVDHRIEILS HDKDYKMKV YEIAEAHYSK LPSRLTK\*

c

## Protein sequence of an internal part of discosoma 2

1 HHMEGSVDGH YFEIKNGGYG KSYDGTNTVK LQVTGGG~~PL~~P FAWPILSPQF QYGNKIFVRH  
61 PEDIADYKKL SFPEGFTWER VMHFEDGGVC CITNDISLEG NCFIYHINFI GLNFP~~SD~~GPV

d

Fig 3

WO 02/42323

PCT/EP01/13604

polythoa 2 fluorescent fusion protein in pGR3

MSDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPK  
YGIRGIPTLLLPKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHSHHSSGLVPRGSGMKETAAAK  
FERQHMDSPDLGTDDDDKAMADIGSEFSTVMSAIKPVMKIELVMEGEVNGHKFTITGEGQKPYEGTQTL  
DLTVTKGVPLPFAFDILSTAFQYGNRVFTKYPDDIPDYFKQTFPEGYSWERTFKYE EGVCTTKSDISLKK  
GQPD CFQYKINFKEKLDPNGPIMQKTLKWEPS TERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDF  
NSTYKAKKT VSF PAYHFVDHRIEILSHNTDYSKVTLYEVAVARNLEHHHHH\*

Fig 4

Polythoa 2 fluorescent fusion protein in pGR7

MSDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPK  
YGIRGIPTLLLPKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHSHHSSGLVPRGSGMKETAAAK  
FERQHMDSPDLGTDDDDKAMADIGSEFYFFESTIMSAIKPVMKIELVMEGEVNGHKFTITGEGQKPYEG  
TQTLNLTVTKGVPPLPFAFDILSTAFQYGNRVFTKYPDDIPDYFKQTFPEGYSWERTFKYE EGVCTTKSDI  
SLKKGQPD CFQYKINFKEKLDPNGPIMRKKTLKWEPS TERMYMDVDKDGAKVLKGDVNAALLLEGGGHY  
RCDFNSTYKAKKT VSF PAYHFVDHRIEILSHNTDYSKVTLYEVAVARN SPLQIMAPQ\*

Fig 5

WO 02/42323

PCT/EP01/13604

(a) pGR1 .....  
 (b) pGR10 .....  
 (c) pGR13 MSDKI IHLTDDSFDTDLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLN  
 (d) pGR16 .....  
 (e) pGR3 MSDKI IHLTDDSFDTDLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLN  
 (f) pGR4 .....  
 (g) pGR5 .....  
 (h) pGR6 .....  
 (i) pGR7 MSDKI IHLTDDSFDTDLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLN  
 (j) pGR8 .....  
 (k) POLYTHOA2 .....  
 consensus

pGR1 .....  
 pGR10 .....  
 pGR13 IDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALS KGQLKEFLDANLAGSGSGHMH  
 pGR16 .....  
 pGR3 IDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALS KGQLKEFLDANLAGSGSGHMH  
 pGR4 .....  
 pGR5 .....  
 pGR6 .....  
 pGR7 IDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALS KGQLKEFLDANLAGSGSGHMH  
 pGR8 .....  
 POLYTHOA2 .....  
 consensus

pGR1 .....MSAIKP  
 pGR10 .....MSAIKP  
 pGR13 HHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMADIGSEFYFESTIMSAIKP  
 pGR16 .....MSAIKP  
 pGR3 HHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMADIGSEFS...TVMSAIKP  
 pGR4 .....MSAIKP  
 pGR5 .....MSAIKP  
 pGR6 .....MSAIKP  
 pGR7 HHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMADIGSEFYFESTIMSAIKP  
 pGR8 .....MSAIKP  
 POLYTHOA2 .....MSAIKP  
 consensus MSAIKP

pGR1 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR10 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR13 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR16 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR3 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR4 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR5 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR6 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR7 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 pGR8 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 POLYTHOA2 VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR  
 consensus VMKIELVMEGEVNGHKFTITGEGQGKPYEGTQTLNLTVTKGVPPLPFAFDILSTAFQYGNR

pGR1 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR10 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR13 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR16 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR3 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR4 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR5 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR6 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR7 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 pGR8 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 POLYTHOA2 VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK  
 consensus VFTKYPDDIPDYFKQTFPEGYSWERTFKYEEGVCTTKSDISLKKGPDCFOYKINFKEGK

Fig 6



WO 02/42323

PCT/EP01/13604

```
pGR1      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR10     LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR13     LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR16     LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR3      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR4      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR5      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR6      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR7      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
pGR8      LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
POLYTHOAZ LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
consensus LDPNGFIMQKKTLLKNEPSTERMYMDVDKDGAKVLKGDVNAALLLEGGGHYRCDFNSTYKA
```

```
pGR1      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR10     KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR13     KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR16     KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR3      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNLEHHHHHH.....
pGR4      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNLEHASRGEYSIVSPKC.....
pGR5      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR6      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR7      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
pGR8      KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
POLYTHOAZ KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ.....
consensus KKTVSFFPAYHFVDHRIEILSHNTDYSKVTLYEVAVARNsPLQIMAPQ
```

```
pGR1      .....
pGR10     .....
pGR13     .....
pGR16     .....
pGR3      .....
pGR4      .....
pGR5      .....
pGR6      .....
pGR7      .....
pGR8      LGTKLDA
POLYTHOAZ .....
consensus
```

Fig 6 (cont'd)

WO 02/42323

PCT/EP01/13604

```

hybridPolyth2-Disc01 .....
pGR14 .....
pGR15 .....
pGR17 .....
pGR18 .....
pGR19 .....
pGR20 .....
pGR21 .....
consensus .....

```

```

hybridPolyth2-Disc01 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR14 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR15 .....SRARVSVITYFESTVMSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR17 .....GEGEGKPYEGTQTLNLTVT
pGR18 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR19 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR20 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
pGR21 .....MSAIKPVVKIELVMEGEVNGHKFTITGEGQGGKPYEGTQTLNLTVT
consensus .....msaikpvmkielvmegevnghkftitGEGqGKPYEGTqtlNltVt

```

```

hybridPolyth2-Disc01 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR14 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR15 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR17 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR18 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR19 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR20 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
pGR21 KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS
consensus KGVPLPFAFDILTAFQYGNRAFTKYPSDIPDYFKQTFPQGYTWERTMNFEDGGVCTVNS

```

```

hybridPolyth2-Disc01 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR14 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR15 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR17 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR18 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR19 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR20 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
pGR21 DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG
consensus DVSLKSGCFEYKIRFDGENFPPNGPVMQKKTVMKEPSTENMYEHDGNLKGDVSRITLLLEG

```

```

hybridPolyth2-Disc01 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR14 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR15 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR17 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR18 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR19 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR20 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
pGR21 GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP
consensus GGHYQCDFKTIYKAKDSQGIKMPYHFVDHRIEILSHDKDYKMKVYIEIAEAHYSKLPSP

```

```

hybridPolyth2-Disc01 LTK
pGR14 LTK
pGR15 LTK
pGR17 LTK
pGR18 LTK
pGR19 LTK
pGR20 LTK
pGR21 LTK
consensus LTK

```

Fig 7

**PCT/EP01/13604**

1598

WO 02/42323

PCT/EP01/13604

**New Figure 8b:**

pGR22	1	MSAIKPVMMKVELVMEGNVNGHKFTITGEGQCKPYEGTHTLNLTVTKGGPLPFAYDILSAA
pGR24	1	MSAIKPVMMKVELVMEGNVNGHKFTITGEGQCKPYEGTHTLNLTVTKGGPLPFAYDILSAA
pGR25	1	MSAIKPVMMKVELVMEGNVNGHKFTITGEGQCKPYEGTHTLNLTVTKGGPLPFAYDILSAA
pGR26	1	MSAIKPVMMKVELVMEGNVNGHKFTITGEGQCKPYEGTHTLNLTVTKGGPLPFAYDILSAA
Polythoa1	1	MSAIKPVMMKVELVMEGNVNGHKFTITGEGQCKPYEGTHTLNLTVTKGGPLPFAYDILSAA
pGR22	61	FQYGNRVFTKYPEDIPDYFKQTFPEGYSWERTFKYDEGLCTTKSDICLKKGEFDCFOYKI
pGR24	61	FQYGNRVFTKYPEDIPDYFKQTFPEGYSWERTFKYDEGLCTTKSDICLKKGEFDCFOYKI
pGR25	61	FQYGNRVFTKYPEDIPDYFKQTFPEGYSWERTFKYDEGLCTTKSDICLKKGEFDCFOYKI
pGR26	61	FQYGNRVFTKYPEDIPDYFKQTFPEGYSWERTFKYDEGLCTTKSDICLKKGEFDCFOYKI
Polythoa1	61	FQYGNRVFTKYPEDIPDYFKQTFPEGYSWERTFKYDEGLCTTKSDICLKKGEFDCFOYKI
pGR22	121	VFEGKNLGPSPGPI MQKKT LKWE PSTERMYMDVDKDGAKVLKGDDNAALLLEGGGHYRCDF
pGR24	121	VFEGKNLGPSPGPI MQKKT LKWE PSTERMYMDVDKDGAKVLKGDDNAALLLEGGGHYRCDF
pGR25	121	VFEGKNLGPSPGPI MQKKT LKWE PSTERMYMDVDKDGAKVLKGDDNAALLLEGGGHYRCDF
pGR26	121	VFEGKNLGPSPGPI MQKKT LKWE PSTERMYMDVDKDGAKVLKGDDNAALLLEGGGHYRCDF
Polythoa1	121	VFEGKNLGPSPGPI MQKKT LKWE PSTERMYMDVDKDGAKVLKGDDNAALLLEGGGHYRCDF
pGR22	181	NSIYKAKKTGSLPAYHWIDHRIEILSHDKDYNKVTMHFAAARNSPFPIMAPC
pGR24	181	NSIYKAKKTGSLPAYHWIDHRIEILSHDKDYNKVTMHFAAARNSPFPIMAPC
pGR25	181	NSIYKAKKTGSLPAYHWIDHRIEILSHDKDYNKVTMHFAAARNSPFPIMAPC
pGR26	181	NSIYKAKKTGSLPAYHWIDHRIEILSHDKDYNKVTMHFAAARNSPFPIMAPC
Polythoa1	181	NSIYKAKKTGSLPAYHWIDHRIEILSHDKDYNKVTMHFAAARNSPFPIMAPC

WO 02/42323

PCT/EP01/13604

## Nucleotide sequence of pGR3

```

1 aattctctac cgatcatgagt gcaattaaac cagtcataaa gattgaattg gtcattggaag
61 gagagggtgaa cgggcacaag ttccacgatca cgggagaggag acaaggcaag ccttacgagg
121 gaacacagac tctagacctt acagtcacta aaggcgtgcc ccttcctttc gctttcgata
181 tcttgtaaac agcattccag tatggcaaca gggatatttac caaataacca gatgatatac
241 cggactatct caagcagacc ttcccggaag gatattcgtg ggaagaagaa ttcaaatatg
301 aagagggcgt ttgcaccaca aagagtgaca taagcctcaa gaaaggccaa ccagactgct
361 ttcaatataa aattaacttt aaaggggaga agcttgaccc caacggccca attatgcaga
421 agaagaccct gaaatgggag ccactccactg agaggatgta catggacgtg gataaagacg
481 gtgcaaaagg gctgaagggc gatgttaaat cggccctgtt gcttgaagga ggtggccatt
541 atcgttgtga cttaacagt acttacaagg cgaagaaaac tgtgtccttc ccagcatatc
601 actttgtgga ccaccgcatt gagattttga gccacaatac ggattacagc aaggttacgc
661 tgtatgaagt tgccgtggct cgcaatctcg agcaccacca ccaccaccac tgagatccgg
721 ctgctaacaa agcccgaaag gaagctgagt tggctgctgc caccgctgag caataactag
781 cataaccctt tggggcctct aaacgggtct tgaggggttt ttgtctgaaa ggaaggaaacta
841 tatccggatt ggcgaatggg acgcgccttg tagcggcgca ttaagcgcgg cgggtgtggt
901 gggttacgcgc agcgtgaccg ctacacttgc cagcgcctta gcgccgctc ctttcgcttt
961 cttcccttcc ttctcgcga cgttcgcggg ctttcccggt caagctctaa atcggggggt
1021 cctcttaggg ttccgattta gtgctttacg gcacctcgac ccaaaaaaac ttgattaggg
1081 tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt tgacgttgga
1141 gtccacgttc ttaaatagtg gactcttggt ccaacttgga accctatctc taaaaaaatga
1201 ggtctattct ttgatttat aagggatttt gccgatttcg gcctattggt taaaaaatga
1261 gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta caatttcagg
1321 tggcactttt cggggaaatg tgcgcggaac ccctatttgt ttatttttct aaatacattc
1381 aaatattgat ccgctcatga gacaataacc ctgataaatg cttcaataat attgaaaag
1441 gaagatgatg agtattcaac atttccgtgt cgcccttatt cctttttttg cggcattttg
1501 ccttcctggt tttgctcacc cagaaacgct ggtgaaagta aaagatgctg aagatcagtt
1561 ggggtgcaga gtgggttaca tcgaactgga tctcaacagc ggttaagatcc ttgagagttt
1621 tcgccccgaa gaacgttttc caatgatgag cactttttaa gttctgctat gtggcgcggt
1681 atttatccgt attgacgcg ggcaagagca actcggctgc cgcatacact attctcagaa
1741 tgacttggtt gagtactcac cagtcacaga aaagcatctt acggatggca tgacagtaag
1801 agaattatgc agtgctgcca taaccatgag tgataacact gcggccaact tacttctgac
1861 aacgatcgga ggaccgaagg agctaaccgc ttttttgcac aacatggggg atcatgtaac
1921 tcgccttgat cgttgggaac cggagctgaa tgaagccata ccaaacgacg agcgtgacac
1981 cagcatgcct gcagcaatgg caacaacggt gcgcaacta ttaactggcg aactacttac
2041 tctagcttcc cggcaacaat taatagactg gatggaggcg gataaagtgt caggaccact
2101 tctgcgctcg gcccttccgg ctggctggtt tattgctgat aaatctggag ccggtgagcg
2161 tgggtctcgc ggtatcattg cagcactggg gccagatggt aagccctccc gttctgtagt
2221 tatctacacg acggggagtc aggcaactat ggatgaacga aatagacaga tcgctgagat
2281 aggtgcctca ctgattaaagc attggtaact gtcagaccaa gtttactcat atatacttta
2341 gattgattta aaacttcatt ttaatttaa aaggatctag gtgaagatcc tttttgataa
2401 tctcatgacc aaaatccctt aacgtgagtt ttctgtccac tgagcgtcag acccgtaga
2461 aaagatcaaa ggatcttctt gagatccttt tttctgcgc gtaatctgct gcttgcaaac
2521 aaaaaaacca ccgctaccag cgggtggttt tttgcggat caagagctac caactctttt
2581 tccgaaggta actggcttca gcagagcgca gataccaaat actgtccttc tagtgtagcc
2641 gtggttaggc caccacttca agaactctgt agcaccgct acatacctcg cttctgtaat
2701 cctgttacca gtggctgctg ccagtggcga taagtctgtt cttaccgggt tggactcaag
2761 acgatagtta ccggataagg cgcagcggtc gggctgaacg ggggggtcgt gcacacagcc
2821 cagcttgag cgaacgacct acaccgaact gagataccta cagcgtgagc tatgagaaag
2881 cggccacgctt ccggaaggga gaaaggcgga caggtatccg gtaagcggca gggctcggaac
2941 aggagagcgc acgagggagc ttccaggggg aaacgcctgg tatctttata gtctgtcgg
3001 gtttcgcaac ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct
3061 atggaaaaac gccagcaacg cggccttttt acggttctct gccttttgct ggccctttgc
3121 tcacatgttc ttctctgctt tatcccttga ttctgtggat aaccgtatta ccgcttttga
3181 gtgagctgat accgctcgcc gcagccgaac gaccgagcgc agcgagtcag tgagcgagga
3241 agcggaagag cgcctgatgc ggtattttct ccttacgcat ctgtcgggta tttcacaccg
3301 catatatggt gcactctcag tacaatctgc tctgatgccg catagttaag ccagtataca
3361 ctccgctatc gctacgtgac tgggtcatgg ctgcgccccg acaccgcca acaccgctg
3421 acgcgccttg acgggcttgt ctgctcccg catccgctta cagacaagct gtgaccgtct

```

Fig 9

WO 02/42323

PCT/EP01/13604

Fig.9 (cont'd)

```

3481 cccgggagctg catgtgtcag aggtttttcac cgtcatcacc gaaacgcgcg aggcagctgc
3541 ggtaaaagctc atcagcgtgg tcgtgaagcg attcacagat gtctgcctgt tcatccgcgt
3601 ccagctcggt gagtttctcc agaagcggtta atgtctggct tctgataaag cgggccatgt
3661 taagggcggt tttttcctgt ttggctactg atgcctccgt gtaaggggga tttctgttca
3721 tgggggtaat gataccgatg aaacgagaga ggatgctcac gatacgggtt actgatgatg
3781 aacatgcccg gttactggaa cgttgtgagg gtaaacact ggcggtatgg atgcggcggtg
3841 accagagaaa aatcactcag ggtcaatgcc agcgcttcgt taatacagat gtaggtgttc
3901 cacagggtag ccagcagcat cctgcgatgc agatccggaa cataatggtg cagggcgctg
3961 acttcccggt ttccagactt tacgaaacac ggaaaccgaa gaccattcat gttgtgtctc
4021 aggtcgcaga cgttttgca cagcagtcgc ttacggttcg ctgcggtatc ggtgattcat
4081 tctgctaacc agtaaggcaa ccccgccagc ctagccgggt cctcaacgac agggacgca
4141 tcatgcgcac ccgtggggcc gccatgccgg cgataatggc ctgcttctcg ccgaaacgtt
4201 tgggtggcgg accagtgcag aaggcttgag cgaggcggtg caagattccg aataccgcaa
4261 gcgacaggcc gatcatcgct gcgctccagc gaaagcggtc ctgcgcgaaa atgaccgaga
4321 gcgtgcggcg cactgtcctc acgagttgca tgataaagaa gacagtcata agtgcgcgga
4381 cgatagtcac gccccgcgcc caccggaagg agctgactgg gttgaaggct ctcaagggca
4441 tcggtcgaga tcccggtgcc taatgagtga gctaacttac attaatgctg ttgcgctcac
4501 tgcccgcctt ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg
4561 cggggagagg cggtttgctg attgggcgcc aggggtggtt ttcttttcc cagtgcgacg
4621 ggcaacagct gattgcctt caccgcctgg cctgagaga gttgcagcaa gcggtccacg
4681 ctggtttgcc ccagcaggcg aaaatcctgt ttgatgggtg ttaacggcgg gatataacat
4741 gagctgtctt cgggtatcgct gtaaccact accgagatgt ccgcaccaac gcgcagcccg
4801 gactcggtaa tggcgcgcat tgcccccagc gccatctgat cgttggcaac cagcatcgca
4861 gtgggaacga tgccctcatt cagcatttgc atgggttgtt gaaaaccgga catggcactc
4921 cagtcgcctt cccgttcgcg tatcggctga atttgattgc gagtgcgata tttatgccag
4981 ccagccagac gcagacgcgc cgagacagaa cttaatgggc ccgctaacag cgcgatttgc
5041 ttggtgacca atgcgaccag atgctccacg cccagtcgcy taccgtcttc atgggagaaa
5101 ataatactgt tgatgggtgt ctggtcagag acatcaagaa ataacgcggg aacattagt
5161 caggcagctt ccacagcaat ggcacctctg tcatccagcg gatagttaat gatcagccca
5221 ctgacgcgtt gcgcgagaag attgtgcacc gccgctttac aggccttcgac gccgcttcgt
5281 tctaccatcg acaccaccac gctggcacc agttgatcgg cgcgagattt aatcgccgcy
5341 acaatttgcy acggcgcggt caggccagaa ctggaggtgg caacgccaat cagcaacgac
5401 gtgttgcccg ccagttgttg tgccacgcgg ttgggaatgt aattcagctc cgccatcgcc
5461 gcttccactt tttcccgctt ttccgcagaa acgtggctgg cctggttcac cagcgggaa
5521 acggtctgat aagagacacc ggcatatctt gcgacatcgt ataacgttac tgggttcaca
5581 ttaccacccc tgaattgat ctcttcggcg cgctatcatg ccataccgcy aaaggttttg
5641 cggccattcga tgggtgcggg gatctcgacg ctctccctta tgcgactcct gcattaggaa
5701 gcagcccagt agtaggttga ggccgttgag caccgcccgc gcaaggatg gtgcatgcaa
5761 ggagatggcg cccaacagtc ccccgccac ggggcctgcc accataccca cggcgaaaca
5821 agcgtcatag agcccgaagt ggcgagcccg atcttccca tcggtgatgt cggcgatata
5881 ggcgcgagca accgcacctg tggcgccggt gatgccggcc acgatgcgtc cggcgtagag
5941 gatcgagatc gatctcgatc ccgcgaaatt aatacgactc actatagggg aattgtgagc
6001 ggataacaat tccctctag aaataatttt gtttaacttt aagaaggaga tatacatatg
6061 agcgataaaa ttattcacct gactgacgac agttttgaca cggatgtact caaagcggac
6121 gggcgcatcc tcgtcgattt ctgggcagag tgggtgcggt cgtgcaaat gatcgcccg
6181 attctggatg aaatcgctga cgaatatcag ggcaaaactga ccgttgcaaa actgaacatc
6241 gatcaaaacc ctggcactgc gccgaaatat ggcatccgtg gtatcccgc tctgctgctg
6301 ttcaaaaacg gtgaagtggc ggcaacaaa gtgggtgcac tgtctaaagg tcagttgaaa
6361 gagttcctcg acgctaacct ggccggttct ggttctggcc atatgcacca tcatcatcat
6421 cattcttctg gtctggtgcc acgcggttct ggtatgaaag aaaccgctgc tgctaaatc
6481 gaacgcgacg acatggacag cccagatctg ggtaccgacg acgacgacaa ggccatggct
6541 gatatcggtat ccg

```

nucleotide sequence of pGR4

```

1 aattctctac cgtcatgagt gcaattaaac cagtcatgaa gattgaattg gtcattggaag
61 gagaggtgaa cgggcacaag ttcacgatca cgggagaggg acaaggcaag cttacgagg
121 gaacacagac tctagacctt acagtcacta aaggcgtgcc ccttccttcc gcttctgata
181 tcttgtcaac agcattccag tatggcaaca ggggtatttac caaatacca gatgatatac
241 cggactattt caagcagacc tttccggaag gatattcgty ggaagaact ttcaaatatg
301 aagaggcggt ttgcaccaca aagagtgaac taagcctcaa gaaaggccaa ccagactgct
361 ttcaatataa aattaacttt aaaggggaga agcttgaccc caacggccca attatgcaga

```

Fig 10

WO 02/42323

PCT/EP01/13604

421 agaagaccct gaaatgggag ccatccactg agaggatgta catggacgtg gataaagacg  
481 gtgcaaaggt gctgaagggc gatgttaatg cggccctggt gcttgaagga ggtggccatt  
541 atcgttgtga ctttaacagt acttacaagg cgaagaaaac tgtgtccttc ccagcatatc  
601 actttgtgga ccaccgcatt gagattttga gccacaatac ggattacagc aaggttacgc  
661 tgtatgaagt tgccgtggct cgcaatctcg agcatgcac tagagggcc tttctatag  
721 tgtcacctaa atgctagagc tcgctgatca gcctcgactg tgccctctag ttgccagcca  
781 tctgtgtgtt gccctcccc cgtgccttcc ttgacctgg aagggtccac tcccactgtc  
841 ctttctaat aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg  
901 ggggggtggg tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct  
961 ggggatgcgg tgggctctat ggcttctgag gcgaaagaa ccagctgggg ctctaggggg  
1021 tatccccacg cgccctgtag cggcgcatga agcggggcgg gtgtgtgtgt tacgcgcagc  
1081 gtgaccgcta cacttgccag cgccctagcg cccgtcctt tcgctttctt cccttctttt  
1141 ctgcccacgt tcgcccggct tcccgtcaa gctctaaatc ggggcatccc tttagggttc  
1201 cgatttagtg ctttacggca cctcgacccc aaaaaacttg attagggtga tggttcacgt  
1261 agtgggcat cgccctgata gaoggttttt cgcccttga cggtggagtc caggttcttt  
1321 aatagtggac tcttgttcca aactggaaca aactcaacc ctatctcggt ctattctttt  
1381 gatttataag ggattttggg gatttcggcc tattggttaa aaaatgagct gatttaacaa  
1441 aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt aggggtgtga aagtcctcag  
1501 gctccccagg caggcagaag agcaggcaga agtatgaaa gcatgcactt caattagtca  
1561 ggaaagtccc caggctcccc agcaggcaga agtatgaaa gcatgcactt caattagtca  
1621 gcaaccatag tcccgcctcc aactccgccc atcccgcctc taactccgct cagttccgct  
1681 cattctccgc cccatggctg actaattttt tttatttatg cagaggccga ggcgctctt  
1741 gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg ctcttgcaaa  
1801 aagctccccg gagcttgatc atccattttt ggatctgagc aagagacagg atgaggatcg  
1861 tttcgcatga ttgaacaaga tggattgcac gcagggtctc cggccgcttg ggtggagagg  
1921 ctattcggct atgactgggc acaacagaca atcggtgctc ctgagccgc cgtgttccg  
1981 ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg acctgtccg tgccctgaat  
2041 gaactgcagg acgaggcagc gcggctatcg tggctggcca cgacggcgct tccctgcgca  
2101 gctgtgctcg acgtgtcac tgaagcggga agggactggc tgctattggg cgaagtgcg  
2161 gggcaggatc tcctgtcatc tcaccttgct cctgccgaga aagtatccat catggctgat  
2221 gcaatgcggc ggctgtcatc gcttgatccg gctacctgcc cattcgacca ccaagcgaaa  
2281 catcgcatcg agcagcagc tactcgatg gaagccggtc ttgtcgatca ggatgatctg  
2341 gacgaagagc atcaggggct cgcgcagcc gaactgttcg ccaggctcaa ggcgcgatg  
2401 cccgacggcg aggatctcgt cgtgacccat ggcgatgcct gcttgcgaa tatcatggg  
2461 gaaaatggcc gcttttcttg attcatcgac tgtggccggc tgggtgtggc ggaccgctat  
2521 caggacatag cgttggtctac ccgtgatatt gctgaagagc ttggcggcga atgggctgac  
2581 cgcttccctg tgctttacg tatcgccgt cccgattcgc agcgcacgc cttctatcg  
2641 cttcttgacg agttcttctg agcgggactc tggggttcga aatgaccgac ctatgaaagg  
2701 ccaacctgcc atcacagat ttcgattcca ccgcgcctt ctatgaaagg ttgggcttcg  
2761 gaactcgttt ccgggacgccc ggctggatga tccctccagc cggggatctc atgctggagt  
2821 tcttcgcccc tttattgcag cttataatgg ttacaaataa agcaatagca  
2881 tcacaaatth cacaataaaa gcaatttttt cactgcattc tagttgtggg ttgtccaaac  
2941 tcatcaatgt atcttatcat gtctgtatac cgtcgacct tagctagagc ttggcgtaat  
3001 catggctcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac  
3061 gagccggaag cataaagtgt aaagcctggg gtgcctaatt agtgagctaa ctcacattaa  
3121 ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat  
3181 gaatcgccca acgcgcgggg agaggcgggt tgcgtattgg gcgctcttc gcttctcgc  
3241 tcaactgact gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg  
3301 cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag  
3361 gccagcaaaa ggccaggaa cgtaaaaagg ccgctgtgct ggcgtttttc cataggctcc  
3421 gccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aaccgcagc  
3481 gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttcga  
3541 ccttcgccc taceggatac ctgtccgct tctcctctc gggaagcgtg gcgctttctc  
3601 aatgctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg  
3661 tgcacgaacc cccggttcag cccgacgct gcgccttatc cggtaactat cgtcttgagt  
3721 ccaaccgggt aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca  
3781 gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca  
3841 ctagaaggac agtatttggg atctgcgctc tgctgaagcc agttaccttc ggaaaaagag  
3901 ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtgtttt tttgtttgca  
3961 agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcccttgatc ttttctacg  
4021 ggtctgacgc tcagtggaa ccaactcac gtttaaggat tttggtcatg agattatcaa  
4081 aaaggatctt cacctagatc cttttaaat aaaaatgaag ttttaaatca atctaaagta

Fig 10 (cont'd)

WO 02/42323

PCT/EP01/13604

4141 tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag  
4201 cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga  
4261 tacgggaggc cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac  
4321 cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc  
4381 ctgcaacttt atccgcctcc atccagtccta ttaattgttg ccgggaagct agagtaagta  
4441 gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac  
4501 gctcgtcgtt tggataggct tcattcagct ccggttccca acgatcaagg cgagtacat  
4561 gatcccccat gttgtgcaaa aaagcgggta gctccttcgg tcctccgcatc gttgtcagaa  
4621 gtaagttggc cgcagtggtta tcactcatgg ttatggcagc actgcataat tctcttactg  
4681 tcatgccatc cgttaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag  
4741 aatagtgtat gcggcgaccg agttgtctct gcccggtcgc aatacgggat aataccgcgc  
4801 cacatagcag aactttaaaa gtgctcatca ttggaaaaag ttcttcgggg cgaaaactct  
4861 caaggatctt accgctgttg agatccagtt cgtgtaaac cactcgtgca ccaactgat  
4921 ctatcagcat ttttacttcc accagcgttt ctgggtgagc aaaaaacagga aggcataatg  
4981 ccgcaaaaaa gggaataagg gcgacacgga aatggtgaat actcatactc ttccttttct  
5041 aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta  
5101 tttagaaaaa taacacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg  
5161 tcgacggatc gggagatctc ccgatccctc atggctgact ctcatgataa tctgctctga  
5221 tgccgcatag ttaagccagt atctgctccc tgcttgtgtg ttggaggtcg ctgagttagt  
5281 cgcgagcaaa atttaagcta caacaaggca aggcttgacc gacaattgca tgaagaatct  
5341 gcttaggggtt aggcgttttg cgtgcttcg cgtgtacgg gccagatata cgcgttgaca  
5401 ttgattattg actagttatt aatagtaatc aattacgggg tcattagtct atagcccata  
5461 ttggagtttc cgcgttacat aacttacggt aatggcccg cctggctgac cgcaccaaga  
5521 cccccgcccc ttgacgtcaa taatgacgta tgttcccata gtaacgcaa tagggacttt  
5581 ccattgacgt caatgggtgg actatttacg gtaaacgtcc cacttgagcag tacatcaagt  
5641 gtatcatatg ccaagtaacg cccctattga cgtcaatgac ggtaaatggc ccgctggga  
5701 tatggccag tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt  
5761 catcgctatt accatggtga tgcggttttg gcagtacatc aatgggctg gatagcgggt  
5821 tgactcacgg ggtattccaa gtctccacc cactgacgtc aatgggagtt tgttttgga  
5881 ccaaaatcaa cgggactttc caaaatgctc taacaactcc gccccattga cgcaaatggg  
5941 cggtaggcgt gtacggtggg aggtctatat aagcagagct ctctggctaa cttagaacc  
6001 cactgcttac tggcttatcg aaattaatac gactcactat agggagaccc aagcttggtg  
6061 ccgagctcgg atccactagt aacggccgcc agtggtctgg

Fig 10  
(cont'd)

nucleotide sequence of PGR5

1 aattcgccct tctggaattc tttaccgtca tgagtgcatt taaaccagtc atgaagattg  
61 aattggtcat ggaaggagag gtgaacgggc acaagttcac gatcacggga gagggacaag  
121 gcaagcctta cgagggaaca cagactctag accttacagt cactaaaggc gtgccccttc  
181 ctttcgcttt cgatactctt tcaacagcat tccagtatgg caacagggta tttaccatct  
241 acccagatga tataccggac tatttcaagc agacctttcc ggaaggatat tctggtgaaa  
301 gaactttcaa atatgaagag ggcgtttgca ccacaaagag tgacataagc ctcaagaaaag  
361 gcccaaccaga ctgctttcaa tataaaatta actttaagg ggagaagctt gaccccaacg  
421 gcccatttat gcagaagaag accctgaaat gggagccatc cactgagagg atgtacatgg  
481 acgtggataa agacggtgca aagggtctga agggcgatgt taatgcggcc ctgttgcttg  
541 aaggaggtgg ccattatcgt tgtgacttta acagtactta caaggcgaag aaaactgtgt  
601 ccttcccagc atatcacttt gtggaccacc gcattgagat tttgagccac aatacggatt  
661 acagcaaggt tacactgtat gaagttgcgg tggctcgcaa ttctctctct cagattatag  
721 cctcgagcat gcacttagag ggccctatcc tatagtgtca cctaaatgct agagctcgct  
781 gatcagcctc gactgtgcct tctagtggcc agccatctgt tgtttgcccc tcccccgctc  
841 cttccttgac cctggaagggt gccactccca ctgtcctttc ctaataaaaat gaggaaattg  
901 catcgatttg tctgagttag tgtcattcta ttctgggggg tgggggtggg caggacagca  
961 agggggagga ttgggaagac aatagcaggc atgctgggga tgcgggtggg tctatggctt  
1021 ctgaggcgga aagaaccagc tgggggtcta gggggtatcc ccacgcgcc tgtagcggc  
1081 cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgtacactt gccagcgccc  
1141 tagcggccgc tctttcgtct tcttccctt cctttctcgc caggttcgcc ggctttcccc  
1201 gtcaagctct aaatcggggc atccctttag ggttccgatt tagtgcttta cggcacctcg  
1261 acccaaaaaa acttgattag ggtgatgggt cagctagtgg gccatcgccc ttagacagcg  
1321 tttttcgccc tttgacgttg gactccacgt tctttaatag tggactcttg ttccaaactg  
1381 gaacaacact caaccctatc tgggtctatt cttttgattt ataagggatt ttggggattt  
1441 cgcctatttg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg  
1501 gaatgtgtgt cagttagggt gtggaaagtc ccagggctcc ccaggcaggc agaagtatgc

Fig 11



WO 02/42323

PCT/EP01/13604

1561 aaagcatgca tctcaattag tcagcaacca ggtgtggaag gtccccaggg tccccagcag  
1621 gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcccg cccctaactc  
1681 cgcccatccc gccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa  
1741 ttttttttat ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagtatg  
1801 gaggaggctt ttttgagggc ctaggctttt gcaaaaagct cccgggagct tgatatcca  
1861 ttttcggatc tgatcaagag acaggatgag gatcgtttcg catgattgaa caagatggat  
1921 tgcacgcagg ttctccggcc gcttgggtgg agaggctatt cggctatgac tgggcacaa  
1981 agacaatcgg ctgctctgat gccgctgtgt tccggctgtc agcgaggggg cggccggttc  
2041 tttttgtcaa gaccgacctg tccggtgccc tgaatgaact gcaggacgag gcagcgcgcc  
2101 tatcgtggct ggccacgacg ggcgttcctt gcgcagctgt gctcgaggtt gtcactgaag  
2161 cgggaaggga ctggctgcta ttggggcgaag tgccggggca ggatctctg tcatctcacc  
2221 ttgctcctgc cgagaaagta tccatcatgg ctgatgcaat gcggcggtcg catacgtctg  
2281 atccggctac ctgccattc gaccaccaag cgaaacatcg catcgagcga gcacgtactc  
2341 ggatggaagc cggctctgtc gatcaggatg atctggacga agagcatcag gggctcgccg  
2401 cagccgaact gtccgcagg ctcaaggcgc gcatgccga cggcgaggat ctcgctgga  
2461 cccatggcga tgctgcttg ccgaatatca tgggtgaaaa tggccgcttt tctggattca  
2521 tgcactgtgg ccggctgggt gtggcgagcc gctatcagga catagcgttg gctaccgctg  
2581 atattgctga agagcttgcc ggcgatggg ctgaccgctt cctcgtgctt tacgggtatcg  
2641 ccgctccgga ttcgcagcgc atcgcttct atcgcttct tgacgagttt tctgagcgg  
2701 gactctgggg ttcgaaatga ccgaccaagc gacgccaac ctgccatcac gagatttcga  
2761 ttccaccgcc gccttctatg aaagggtggg cttcggaatc gttttccggg acgcccggctg  
2821 gatgacctc cagcgcgggg atctcatgct ggagttcttc gccaccacca acttggttat  
2881 tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt  
2941 tttttcactg cattctagtt gtgggttctc caaactcctc aatgtatctt atcatgtctg  
3001 tataccgtcg acctctagct agagcttggc gtaatcatgg tcatagctgt ttcctgtgtg  
3061 aaattgttat ccgctcacaa ttccacacaa catacagacc ggaagcataa agtgtaaaagc  
3121 ctgggggtgcc taatgagtga gctaactcac attaatgctg ttgcgctcac tggccgcttt  
3181 ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgag cggggagagg  
3241 cggtttgctg attggcgctt cttccgcttc ctgcgtcact gactcgctgc gctcggctgt  
3301 tccggtcgcg cgagcggtat cagctcactc aaaggcggtg atacggttat ccacagaatc  
3361 aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtta  
3421 aaaggccgga ttgctggcgt tttccatag gctccgccc cctgacgagc atcacaaaa  
3481 tgcagctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc  
3541 ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc  
3601 cgcctttctc ccttcgggaa gcgtggcgct ttctcaatgc tcacgctgta ggtatctcag  
3661 tccgtgtgag gtcgttcgct ccaagctggg ctgtgtgcac gaacccccg ttcagccga  
3721 ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc  
3781 gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgtac  
3841 agagttcttg aagtgggtgg ctactacagg ctacactaga aggacagtat ttggtatctg  
3901 cagctcgtcg aagccagtta ctttcggaaa aagagttggg agctcttgat cggcaaaaa  
3961 aaccaccgct ggtagcgggt gtttttttgt ttgcaagcag cagattacgc gcagaaaaa  
4021 aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa  
4081 ctacagttaa gggatttttg tcatgagatt atcaaaaagg atcttcacct agatcctttt  
4141 aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaaact ggtctgacag  
4201 ttaccaatgc ttaatcagtg aggcacctat ctacgcgac tgctctattt gttcatccat  
4261 agttgcctga ctcccgtcg tgtagataac tacgatacgg gagggcttac catctggccc  
4321 cagtgctgca atgataccgc gagaccacg ctacccggct ccagatttat cagcaataaa  
4381 ccagccagcc ggaaggccg agcgcagaag tggctcgtga actttatccg cctccatcca  
4441 gtcctattaat tgggtcgggg aagctagagt aagtagttcg ccagttataa gtttgcgcaa  
4501 cgttgttgcc attgctacag gcacgtgggt gtcacgctcg tcgtttggta tggcttcatt  
4561 cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc  
4621 ggttagctcc ttccgtcctc cgtcgtttgt cagaagtaag ttggccgcag tggttatcact  
4681 catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgctttt  
4741 tgtgactggg gactactcaa ccaagtcatt ctgagaatag tgtagcggc gaccgagttg  
4801 ctcttgcccg gcgtcaatac gggataatac cgcgcacat agcagaactt taaaagtgtc  
4861 catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc  
4921 cagttcgatg taaccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag  
4981 cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taaggcgac  
5041 acggaaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg  
5101 ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaatagggtt  
5161 tccgcgcaca tttccccgaa aagtgcacc tgacgtcgac ggaatgggag atctcccgat  
5221 cccctatggg cgactctcag tacaatctgc tctgatgccg catagttaag ccagtatctg

Fig 11 (cont'd)

WO 02/42323

PCT/EP01/13604

5281 ctccctgctt gtgtgttga ggtcgctgag tagtgccga gcaaaattta agctacaaca  
 5341 aggcaggct tgaccgacaa ttgcatgaag aatctgctta gggtaggcg ttttgcgctg  
 5401 cttcgcatg tacgggccag atatacgcgt tgacattgat tattgactag ttattaatag  
 5461 taatcaatta cggggtcatt agttcatagc ccatatatgg agttccgcgt tacataactt  
 5521 acggtaaatg gccgcctgg ctgaccgccc aacgacccc gccattgac gtcaataatg  
 5581 acgtatgttc ccatagtaac gccaataggg actttccatt gacgtcaatg ggtggactat  
 5641 ttacggtaaa ctgccactt ggcatgacat caagtgtatc atatgccaa gtcgccctt  
 5701 attgacgtca atgacggtaa atggccgcc tggcattatg cccagtacat gaccttatgg  
 5761 gactttccta ctggcagta catctacgta ttagtcacg ctattaccat ggtgatgcg  
 5821 ttttggcagt acatcaatgg gcgtggatag cggtttgact cacggggatt tccaagtctc  
 5881 caccctatg acgtcaatgg gagtttgttt tggcaccaaa atcaacggga ctttccaaaa  
 5941 tgtcgttaaca actccgcccc attgacgcaa atggcgcgta ggctgtacg gtgggaggtc  
 6001 tatataagca gagctctctg gctaactaga gaaccactg ctactggct tatcgaaatt  
 6061 aatacgactc actataggga gacccaagct tggtagcgag ctggatcca ctagtaacgg  
 6121 ccgccagtg gctgg

Fig 11  
(cont'd)

## Nucleotide sequence of pGR6

1 tcgagatgca tggccggcgg agctccgcat cggccgctgt catcagatcg ccatctcgcg  
 61 cccgtgcctc tgacttctaa gtccaattac tcttcaacat cctacatgc tcttctccc  
 121 tgtgtcccca cccctatatt ttgttattat caaaaaaact tcttcttaat tcttctgttt  
 181 tttagcttct ttttaagtac ctctaacaat gaaattgtgt agattcaaaa atagaattaa  
 241 ttcgtaataa aaagtcgaaa aaaattgtgc tccctcccc cattaataat aattctatcc  
 301 caaaatctac acaatgttct gtgtacactt cttatgtttt ttttacttct gataaatttt  
 361 ttttgaaaca tcatagaaaa aaccgcacac aaaatacctt atcatatgtt acgtttcagt  
 421 ttatgaccgc aatttttatt tcttcgcacg tctgggcctc tcatgacgtc aaatcatgct  
 481 catcgtgaaa aagttttgga gtatttttgg aatttttcaa tcaagtgaaa gtttatgaaa  
 541 ttaatttttc tgcttttgc ttttgggggt tccccattt gtttgtcaag agtttcgagg  
 601 acggcgtttt tcttgctaaa atcacaagta ttgatgagca cgatgcaaga aagatcgga  
 661 gaagggttgg gtttgaggct cagtggagg tgagtagaag ttgataattt gaaagtggag  
 721 tagtgtctat ggggttttgg ccttaaatga cagaatacat tcccaatata ccaaacataa  
 781 ctgtttccta ctagtccggc gtacgggccc tttcgtctcg cgcgttcgg tgatgacggt  
 841 gaaaacctct gacacatgca gctccggag acggtcacag cttgtctgta agcggatgcc  
 901 gggagcagac aagcccgta gggcgctca gcggtgttg gcggtgtcg gggctggctt  
 961 aactatgcgg catcagagca gattgtactg agagtgcacc atatgcggtg tgaaataaccg  
 1021 cacagatgcg taaggagaaa ataccgcatc aggcggcctt aagggcctcg tgatacgcct  
 1081 atttttatag gttaatgtca tgataataat ggtttcttag acgtcagggt gcaactttcg  
 1141 gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa atatgtatcc  
 1201 gctcatgaga caataacctt gataaatgct tcaataatat tgaaaaagga agagtatgag  
 1261 tattcaacat ttcgtgtcg ccttatttc ctttttgcg gcattttgcc ttcctgtttt  
 1321 tgcctaccga gaaacgctgg tgaaagttaa agatgctgaa gatcagttgg gtgcacgagt  
 1381 gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaga  
 1441 acgttttcca atgatgagca cttttaaagt tctgtatagt ggcgcgggat tatcccgat  
 1501 tgacgcgggg caagagcaac tcggtcgccc catacactat tctcagaatg acttggttga  
 1561 gtactaccga gtcacagaaa agcatcttac ggtatggcatg acagtgaag aattatgcag  
 1621 tgctgccata accatgagtg ataactatgc ggccaactta cttctgacaa cgatcggagg  
 1681 accgaaggag ctaaccgctt ttttgacaaa catgggggat catgtaactc gccttgatcg  
 1741 ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt  
 1801 agcaatggca acaacgttgc gcaaaactatt aactggcgaa ctacttactc tagcttccc  
 1861 gcaacaatta atagactgga tggaggcgga taaagtgtca ggaccacttc tgcgtcggc  
 1921 ccttcgggct ggtgtgttta ttgctgataa atctggagcc ggtgagcgtg ggtctcggc  
 1981 tatcattgca gcaactgggc cagatggtta gccctccggt atcgtagtta tctacacgac  
 2041 ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact  
 2101 gattaagcat ttgtaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa  
 2161 acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa  
 2221 aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaagg  
 2281 atcttcttga gatccttttt tctgcgcgt aatctgctgc ttgcaaaaca aaaaaccacc  
 2341 gctaccagcg gtggtttgtt tgcggatca agagctacca actcttttct cgaaggtaac  
 2401 tggcttcagc agagcgagca taccaaatac tgtccttcta gtgtagcgt agttaggcca  
 2461 ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaactc tgttaccagt  
 2521 ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac gatagtacc  
 2581 ggataaggcg cagcggctcg gctgaacggg gggttcgtgc acacagccca gcttgagcgc

Fig 12

WO 02/42323

PCT/EP01/13604

Fig 12 (cont'd)

```

2641 aacgacctac accgaactga gatacctaca gcgtgagcat tgagaaagcg ccacgcttcc
2701 cgaaggcgaga aaggcgagaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac
2761 gagggagctt ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct
2821 ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc
2881 cagcaacgcg gcctttttac ggttcttggc cttttgctgg cctttgtctc acatgttctt
2941 tcctgcgtta tcccctgatt ctgtggataa ccgatttacc gcctttgagt gagctgatac
3001 cgctcgccgc agccgaacga ccgagcgag cgagtcagt agcgaggaag cggagagagc
3061 cccaatacgc aaaccgcctc tcccgcgcg tgggccgatt cattaatgca gctggcacga
3121 caggtttccc gactggaag cgggcagtga gcgcaacgca attaatgtga gttagctcac
3181 tcattaggca ccccagcctt tacactttat gcttccggct cgtatgttgt gtggaattgt
3241 gagcggataa caatttcaca caggaaacag ctatgacct gattacgcca agcttgcatt
3301 cctgcaggtc gactctagag gatccccagc ttgcatgcct gcaggtcgag gcatttgaat
3361 tgggggtggt ggacagtaac tgtctgtaat aataattact cctgaccagg ttgcaattcg
3421 agttttgata agcataatta taccttgtag attgtgggtt ttgtgctgtg gacgttttat
3481 tgtggacatc cccataagct acaagaaccc aaaaatgaaa ttaaaagtat tgaaaaacgt
3541 cgtaacattt tatatctgag tagtatcctt tgctttaaat gtccataaaa ataattttat
3601 aatcaataaa acaacgtttg taaatcaact gagtttaca gtagagacat tgagggatac
3661 tttcactatg ctaaagtga taaatcgacca aataataact cactttggta tttattcctg
3721 tcttataatg tttatgtatg attaaattca tatgcatatg gctcactctg acaaaaaaat
3781 ataactcttc agatcaatat tgactaccga tgcgggtggt cttttgcttt gaattctgct
3841 gaactttaca ccccgaacag caatgtgtgc ttcagctaaa aaaaagtaag tgtgttaatc
3901 agtccccccg attcttcatt ttttggccct ctctcccggt tcgtcgcaa aagaagagaa
3961 aataaagata agtctcaaga taggttggtg atcgctaaag tgggtgtgtg gafaagagta
4021 gcaaaatggc aggaagagca ctttgcgcgc acacactgta ctcatgttgc tggataaaat
4081 tctctcggtt tttgcccgtc gatgtctgcc tctctgccat tgagccggct tcttcactat
4141 ctttagttaa cctaaaatgc cgtttctttt ctctgatccc actatccgtt gaggttctct
4201 gctctcttcg ctcccttacc gccagcgagc aactatccgt gggggcgcc tgcctggaag
4261 atggggggga agaaaagaag tttttgctat ttgcaattga gaaagagact tttcctgctg
4321 cgatgggttag agaacagtgt gcagacactt ttcagctacc tagatacatg gatatccccg
4381 cctcccaatc caccacccca gggaaaaaga agggctcgcc gaaaaatcaa agttatctcc
4441 aggtcgcgcg atcccaccca gcggttgact tctctccacc acttttcatt ttaaccctcg
4501 gggtaacggg ttggccaaag gacccaaagg tatgtttcga atgatactaa cataacatag
4561 aacattttca ggaggacct tggctagcgt cgacggtacc atggggcgcg ccaccaccat
4621 gagtgcaatt aagccagtta tgaagattga attggtcatg gaaggagagg tgaacgggca
4681 caagttcacg atcacgggag agggacaagg caagccttac gagggaacac agactctaaa
4741 ccttaacagc actaaaggcg tgccccttcc tttcgttttc gatatactgt caacagatt
4801 ccagtatggc aacagggtat ttaccaataa cccagatgat ataccggact atttcaagca
4861 gacctttccg gaaggatatt cgtgggaaag aactttcaaa tatgaagagg gcgtttgcac
4921 cacaaagagt gacataagcc tcaagaagg ccaaccagac tgctttcaat ataaaattaa
4981 ctttaaggg gagaagcttg accccaacgg cccaattatg cagaagaaga cagaataatg
5041 ggagccatcc actgagagga tgtacatgga tgtggataaa gacggtgcaa aggtgtgaa
5101 gggcgatgtt aatgcggccc tgttgcttga aggagggcgc cattatcggt gtgactttaa
5161 cagtacttac aaggcgaaga aaactgtgtc cttccagca tatcactttg tggaccaccg
5221 cattgagatt ttgagccaca atacggatta cagcaagggt acactgtatg aagttgcccg
5281 ggctcgcaat tctcctcttc agattatggc gcccagtaa aggtttaacg aaaagccaag
5341 actc

```

## Nucleotide sequence of pGR7

```

1 aattctatta ctttgagtct accatcatga gtgcaattaa accagtcatt aagattgaat
61 tgggtcatgga aggagaggtg aacgggcaca agttcacgat cacgggagag ggacaaggca
121 agccttacga gggaaacacg actctaaacc ttacagtcac taaaggcgtg ccccttccct
181 tcgctttcga tatcttgtca acagcattcc agtatggcaa cagggtattt accaaatacc
241 cagatgatat accggactat ttcaagcaga cctttccgga aggatattcg tgggaaagaa
301 ctttcaataa tgaagagggc gtttgacca caaagagtga cataagctc aagaaaggcc
361 aaccagactg ctttcaatat aaaattaact ttaaagggga gaagcttgac cccaacggcc
421 caattatgcy gaagaagacc ctgaaatggg agccatccac tgagaggatg tcatggatg
481 tggataaaga cgggtgcaag gtgctgaagg gcgatgttaa tgccggccctg ttgcttgaag
541 gagggcgcca ttatcgttgt gactttaaca gtacttaca ggccaagaaa actgtgtcct
601 tcccagcata tcactttgtg gaccaccgca ttgagatttt gagccacaat acggattaca
661 gcaaggttac actgtatgaa gtgtccgtgg ctgcgaattc tctcttcag attatggcg
721 cccagtaaa gcttaacgaa aagccaagac gctcgagcac caccaccacc accactgaga

```

Fig 13

WO 02/42323

PCT/EP01/13604

781 tccggctgct aacaaagccc gaaaggaagc tgagttggct gctgccaccg ctgagcaata  
841 actagcataa ccccttgggg cctctaaacg ggtcttgagg gggtttttgc tgaaggagg  
901 aactatatacc ggattggcga atgggacgcg cctgttagcg gcgcattaaag cgcggcgggt  
961 gtgggtggta cgcgcagcgt gacgcgtaca cttgccagcg ccttagcgcc cgtcctttc  
1021 gctttcttcc cttcctttct cgcacggtc gccggettcc cccgtcaagc tctaaatcgg  
1081 gggctccctt tagggttccg atttagtgct ttacggcacc tcgaccccaa aaaactgat  
1141 taggggtgat gttcacgtag tgggccatcg cctgataga cggtttttcg ccctttgacg  
1201 ttggagtgca cgttctttta tagtggactc ttgttccaaa ctggaacaac actcaacct  
1261 atctcggctc attcttttga ttataaagg attttgccga ttccggccta ttggttaaaa  
1321 aatgagctga tttaacaaaa atttaacgcg aattttaaca aaatattaac gtttacaatt  
1381 tcagggtggca cttttcgggg aaatgtgcgc ggaacccta ttgtttatt ttctaaata  
1441 cattcaataa tgtatccgct catgagacaa taacctgat aaatgcttca ataatttga  
1501 aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgccgca  
1561 ttttgccctc ctgtttttgc tcaccagaa acgctggtga aagtaaaaga tgcataagat  
1621 cagttgggtg cacgagtggt ttacatcgaa ctggatctca acagcggtaa gatccttgag  
1681 agttttcgcc ccgaagaacg ttttccaatg atgagcactt ttaaagtctt gctatgtggc  
1741 gcgggtattat cccgtattga cgcggggcaa gagcaactcg gtcgcgcgat acactattct  
1801 caaagtgact tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca  
1861 gtaagagaat tatgacgtgc tgccataacc atgagtgaata acactgcggc caacttactt  
1921 ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat  
1981 gtaactcgcc ttgatcggtg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt  
2041 gacaccacga tgcctgcagc aatggcaaca acgttgcgca aactattaac tggcgaacta  
2101 cttactctag cttccgggca acaattaata gactggatgg aggcggataa agttcgagga  
2161 ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc tggagccgggt  
2221 gagcgtgggt ctcgcggtat cattgcagca ctggggccag atggttaagcc ctcccgatc  
2281 gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct  
2341 gagataggtg cctcactgat taagcattgg taactgtcag accaagttta ctcatatata  
2401 ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt  
2461 gataatctca tgaccabaaat ccttaacgt gagttttcgt tccactgagc gtcagacccc  
2521 gtagaaaaga tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg  
2581 caaacaaaaa aaccaccgct accagcgggt gtttgtttgc cggatcaaga gctaccaact  
2641 ctttttccga aggttaactgg cttcagcaga gcgcagatac caaataactgt ccttctagt  
2701 tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgtctg  
2761 ctaatcctgt taccagtggtg tgctgccagt ggcgataagt cgtgtcttac cgggttggac  
2821 tcaagacgat agttaccgga taaggcgagc cggtcggggg gaacgggggg tctgtgaca  
2881 cagcccagct tggagcgaac gacctacacc gaactgagat acctacagc tgagctatga  
2941 gaaagcgcca cgtctcccgga agggagaaag gcggacaggt atccggttaag cggcagggtc  
3001 ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagctct  
3061 tcegggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg  
3121 agcctatgga aaaacgccag caacgcggcc tttttacggt tccctggcct ttgctggcgt  
3181 tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgce  
3241 tttgagtgag ctgataccgc tcgcgcgagc cgaacgaccg agcgcagcga gtcagttagc  
3301 gaggaagcgg aagagcgctt gatgcggtat tttctctta cgcactgtg cggatttca  
3361 caccgcatat atggtgcact ctgactacaa tctgctctga tggcgcatag ttaagccagt  
3421 atacactccg ctatcgctac gtgactgggt catggctgag ccccgacacc cgccaacacc  
3481 cgtgacgcg cctgacgggg cttgtctgct cccggcatcc gcttacagac aagctgtgac  
3541 cgtctccggg agctgcagt gtccagaggt ttaccgctca tcaccgaaac gcgcgaggca  
3601 gctgcggtaa agctcatcag cgtggtcgtg aagcgattca cagatgtctg cctgttcatc  
3661 cgcgtccagc tcgttgagtt tctccagaag cgttaatgtc tggcttctga taaagcgggc  
3721 catgttaagg cgggtttttt cctggttggt cactgatgcc tccgtgtaag ggggatttct  
3781 gttcatgggg gtaatgatac cgatgaaacg agagaggatg ctacagatac gggttactga  
3841 tgatgaacat gcccggttac tggaaacgtt tgagggtaaa caactggcgg tatggatgcg  
3901 gcgggaccag agaaaaatca ctcagggtca atgccagcgc ttcgttaata cagatgtagg  
3961 tgttccacag ggtagccagc agcatcctgc gatgcagatc cggaaacataa tggtagcagg  
4021 cgtgacttc cgcgtttcca gactttacga aacacggaaa ccgaagacca ttcattgtgt  
4081 tctcaggtc gcagacgttt tgacagcaga gtcgcttcac ttccgctcgc gtagcgtga  
4141 ttcattctgc taaccagtaa ggcaaccccg ccagcctagc cgggtcctca acgacaggag  
4201 cacgatcatg cgcacccgtg gggccgcat gccggcgata atggcctgct tctcgccgaa  
4261 acgtttggtg gcgggaccag tgacgaaggc ttgagcgagg gcgtgcaaga ttcgaatac  
4321 cgcaagcgac aggcggatca tcgtcgcgct ccagcgaaag cggctcctgc cgaataatgac  
4381 ccagagcgct gccggcacct gtccatcgag ttgcatgata aagaagacag tcataagtg  
4441 ggcgacgata gtcattgccc gcgcccaccg gaaggagctg actgggttga aggtctcaa

Fig 13 (cont'd)

WO 02/42323

PCT/EP01/13604

Fig 13 (cont'd)

4501 gggcatcggt cgagatcccg gtgcctaagt agtgagctaa cttacattaa ttgcgttgcg  
 4561 ctactgccc gctttccagt egggaacct gtctgcccag ctgcattaat gaatcgcca  
 4621 acgcgcggg agaggcggtt tgcgtattgg gcgccagggt gggttttctt ttcaccagt  
 4681 agacgggcaa cagctgattg cccttcaccg cctggccctg agagagttgc agcaagcggt  
 4741 ccacgctggg ttgccccagc aggcgaaaat cctgtttgat ggtggttaac ggcgggatat  
 4801 aacatgagct gtcttcggta tcgtctgtat ccactaccga gatgtccgca ccaacgcgca  
 4861 gcccgactc ggtaatggcg cgcattgcgc ccagcgccat ctgatcgttg gcaaccagca  
 4921 tcgcagtggt aacgatgccc tcattcagca ttgcatggt ttgttgaaaa ccggacatgg  
 4981 cactccagtc gccttccegt tccgctatcg gctgaatttg attgcgagtg agatatttat  
 5041 gccagccagc cagacgcaga cgcgcgcaga cagaacttaa tgggcccgt aacagcgca  
 5101 tttgctggtg acccaatgcg accagatgct ccagcccag tcgctgaccg tcttca tggg  
 5161 agaaaaataat actgttgatg ggtgtctggt cagagacatc aagaaaaaac gccggaacat  
 5221 tagtgacggc agcttccaca gcaatggcat cctggctatc cagcggtatg ttaatgatca  
 5281 gcccactgac gcgttgccg agaaagattgt gcaccgccc tttacaggct tcgacgcgc  
 5341 ttctgtctac catcgacacc accacgctgg caccagttg atcgccgca gatattaatc  
 5401 ccgcgacaat ttgcgacggc gcgtgcaggg ccagactgga ggtggcaacg ccaatcagca  
 5461 acgactggtt gcccgccagt tgttgtgcca cgcggttggg aatgtaattc agctccgcca  
 5521 tcgcegttc cactttttcc cgcgttttcg cagaaacgtg gctggcctgg ttcaccacgc  
 5581 gggaaacggg ctgataagag accacggcat actctgcgac atcgataaac gtactggtt  
 5641 tcacattcac caccctgaat tgactctctt ccgggcgcta tcatgccata ccgcgaaagg  
 5701 ttttgcgcca ttctgatggtg tccgggatct cgaagctctc ccttatgcga ctctgcatt  
 5761 aggaagcagc ccagtagtag gttgagccg ttgagcaccg ccgcccgaag gaatggtgca  
 5821 tgcaaggaga tggcgcccaa cagtcctccg gccacggggc ctgccaccat accacgcgc  
 5881 aaacaagcgc tcatgagccc gaagtggcga gcccgatctt ccccatcggt gatgtcgcg  
 5941 atataggcgc cagcaaccgc acctgtggcg ccggtgatgc cggccacgat gcgtccggcg  
 6001 tagaggatcg agatcgatct cgatcccgcg aaattaatac gactcactat aggggaattg  
 6061 tgagcggata acaattcccc tctagaaata atttgttta actttaagaa ggagataatc  
 6121 atatgagcga taaaattatt cacctgactg acgacagttt tgacacggat gtaactcaag  
 6181 cggacggggc gatcctcgtc gatttctggg cagagtgggt cgggtccgtgc aaaatgatcg  
 6241 ccccgattct ggtgaaatc gctgacgaat atcagggcaa actgacggtt gcaaaactga  
 6301 acatcgatca aaaccctggc actgcgcgca aatatggcat ccgtggatc ccgactctgc  
 6361 tgctgttcaa aaacgggtgaa ttggcgccaa ccaagtggtg tgactgtct aaagtcagt  
 6421 tgaaagagtt cctcgacgct aaactggcgg gttctggttc tggccatatg caccatcatc  
 6481 atcatcattc ttctggtctg gtgcccagcg gttctggtat gaaagaaacc gctgctgcta  
 6541 aattcgaacg ccagcacatg gacagcccag atctgggtac cgacgacgac gacaaggcca  
 6601 tggctgatat cggatccg

nucleotide sequence of pDW2700

1 gatccccagc ttgcatgcct gcaggctcag gcatttgaat tgggggtggt ggacagtaac  
 61 tgtctgtaat aataattact cctgaccagg ttgcaattcg agttttgata agcataatta  
 121 tacctgttac attgtgggtt ttgtgctgtg gacgttttat tggggacatc ccataagct  
 181 acaagaaacc aaaaatgaaa ttaaaagtat tgaaaaacgt cgtaacattt tatactctgag  
 241 tagtatcctt tgcttttaaa gtccataaaa ataattttat aatcaataaa acaacgtttg  
 301 taaatcaact gagtttacaa gttagagacat tgagggatac tttactatg ctaaaagtga  
 361 taatcgacca aataataact cacttttgta tttattcctg tcttataatg ttatgtatga  
 421 attaaattca tatgcatatg gctcactctg acaaaaaaaa ataactctcc agatcaatat  
 481 tgactaccga tgcgggtggt cttttgcttt gaattctgct gaactttaca ccccgacag  
 541 caatgtgtgc ttcagctaaa aaaaagtaag tgtgttaatc agtccccccg attcttcatt  
 601 ttttgccctc ctctccggtt tcgtcggcaa aagaagagaa aataaagata agtctcaaga  
 661 taggttggtg atcgctaaag tgggtgtgtg gataagagta gcaaaatggc aggaagagca  
 721 ctttgccgca acacactgta ctcatgttgc tggataaaat tctctcgttg tttgcccgtg  
 781 gatgtctgcc tctctgccat tgagccggtc tcttcaactat ctttagttaa cctaaaaatg  
 841 cgtttctttt ctctatccc actatccgtt gaggttctct gctctcttcg ctcccttacc  
 901 gccagcgagc aactatccgt gggggcgccct tgctcgggag atggggggga agaaagaaga  
 961 tttttgctat ttgcacttga gaaagagact tttcctgcgt cgatgggttag agaacagtgt  
 1021 gcagacactt ttcagctacc tagatacatg gatatcccg cctcccaatc caccaccca  
 1081 gggaaaaaga agggctcgcg gaaaaatcaa agttatctcc aggtcgcgc atcccaacca  
 1141 gcggttgact tctctccacc acttttcatt ttaaccctcg gggtagcgga ttggccaaag  
 1201 gacccaaagg tatgtttcga atgatactaa cataacatag aacattttca ggaggacct  
 1261 tggctagcgt cgacgggtacc atggggcgcg ccgaattcgt taactgatca ctcgagatgc  
 1321 atggccggcc gagctccgca tcggccgctg tcatcagatc gccatctcgc gcccgctgct

Fig 14

WO 02/42323

PCT/EP01/13604

1381 ctgacttcta agtccaatta ctcttcaaca tccctacatg ctctttctcc ctgtgctccc  
1441 accccctatt tttgttatta tcaaaaaaac ttcttcttaa tttctttgtt ttttagcttc  
1501 ttttaagtca cctctaacia tgaaatttg tagattcaaa aatagaatta attcgtata  
1561 aaaagtcgaa aaaaattgtg ctccctcccc ccattaataa taattctatc ccaaaatcta  
1621 cacaatgttc tgtgtacact tcttatgttt tttttacttc tgataaattt tttttgaaac  
1681 atcatagaaa aaaccgcaca caaaatacct tatcatatgt tacgtttcag tttatgaccg  
1741 caatttttat ttcttcgcac gtctgggct ctcatgacgt caaatcatgc tcatcgtgaa  
1801 aaagtttttg agtatttttg gaatttttca atcaagtga agtttatgaa attaattttc  
1861 ctgcttttgc tttttggggg tttccctat tgtttgtcaa gagtttcgag gacggcggtt  
1921 ttcttgctaa aatcacaagt attgatgagc acgatgcaag aaagatcgga agaaggttg  
1981 gggttgaggc tcagtggag gtgagtagaa gttgataatt tgaaagtga gtagtgccta  
2041 tgggggtttt gccttaaatg acagaataca ttcccaatat accaaacata actgtttcct  
2101 actagtcggc cgtacgggac ctttcgtctc gcgcgtttcg gtgatgacgg tgaaaacctc  
2161 tgacacatgc agctcccgga gacggctaca gcttgtctgt aagcggatgc cgggagcaga  
2221 caagcccgctc agggcgcgctc agcgggtgtt ggoggggtgtc ggggtctggc taactatgcg  
2281 gcatacagagc agattgtact gagagtgcac catatgcggt tgaaataacc gcacagatgc  
2341 gtaaggagaa aataccgcat caggcggtct taaggcgctc gtgatacgcc tatttttata  
2401 gggttaatgtc atgataataa tgggtttctta gacgtcaggt ggcacttttc ggggaaatgt  
2461 gcgcggaacc cctattttgt ttttttctta aatacattca aatatgtatc cgctcatgag  
2521 acaataaccc tgataaatgc ttcaataata ttgaaaaagg aagagtatga gtattcaaca  
2581 tttccgtgtc gcccttattc ctttttttgc ggcattttgc ctctctgttt ttgctcaccc  
2641 agaaacgctg gtgaaagtta aagatgctga agatcagttg ggtgcacgag tgggttacat  
2701 cgaactggat ctcaacagcg gtaagatcct tgagagtttt cgcccggaag aacgttttcc  
2761 acgtatgagc acttttaaa ttctgtatg tggcgcggtta ttatcccgta ttgacgcgg  
2821 gcaagagcaa ctcggctgcc gcatacacta ttctcagaat gacttggttg agtactcacc  
2881 agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca gtgctgccat  
2941 aaccatgagt gataaacatg cggccaactt acttctgaca acgatcgag gaccgaagga  
3001 gctaaccgct tttttgcaca acatggggga tcatgtaact cgcttgatc gttgggaacc  
3061 ggagctgaat gaagccata caaacgacga gcgtgacacc acgatgcctg tagcaatggc  
3121 aacaacgttg cgcacaactat taactggcga actacttact ctacttccc ggcaacaatt  
3181 aatagactgg atggaggcgg ataaagtgc aggaccactt ctgcgctcgg ccttccggc  
3241 tggctggttt attgctgata aatctggagc cggtagcgt gggctctcgc gtatcatg  
3301 agcactgggg ccagatggta agccctcccg tatcgtatgt atctacagca cggggagta  
3361 ggcaactatg gatgaacgaa atagacagat cgtgagata ggtgcctcac tgattaagca  
3421 ttggttaactg tcagaccaag ttactcata tatactttag attgatttaa aacttcattt  
3481 ttaattttaa aggatctagg tgaagatcct ttttgataat ctcatgacca aaatccctta  
3541 acgtgagttt tcgttccact gagcgtcaga cccgtagaa aagatcaaag gatcttcttg  
3601 agatcctttt tttctgcgcg taatctgctg cttgcaaaaca aaaaaccac cgctaccagc  
3661 ggtggtttgt ttgccggatc aagagctacc aactctttt ccgaaggtaa ctggctcag  
3721 cagagcgagc ataccaata ctgtccttct agttagccg tagttaggcc accactcaa  
3781 gaactctgta gcaccgccta catacctcgc tctgctaate ctgttaccag tggctgctgc  
3841 cagtggcgat aagtcgtgtc ttaccgggtt ggaactaaga cgatagttac cggataaggc  
3901 gcagcggtcg ggtgaaacgg ggggttcgtg cacacagccc agcttgagc gaacgaccta  
3961 caccgaactg agatacctac agcgtgagca ttgagaaagc gccacgcttc ccgaaggag  
4021 aaagcgggac aggtatccgg taagcgcgag ggtcggaaca ggagagcgca cgaggagct  
4081 tccaggggga aacgcctggt atctttatag tctgtcggg tttcgccacc tctgactga  
4141 gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg ccagcaacgc  
4201 ggccttttta cggttcctgg ctttttctg gccttttct cacatgtct ttcctgcgtt  
4261 atccctgat tctgtggata accgtattac cgcttttgag tgagctgata ccgctcgcg  
4321 cagccgaacg accgagcgca gcagtcagt gagcgaggaa gcggaagagc gccaataacg  
4381 caaacgcct ctcccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc  
4441 cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agttagctca ctcattaggc  
4501 acccaggtt ttacacttta tgcttcggc tcgtatgtt tgggaattg tgagcgata  
4561 acaatttcac acaggaaaca gctatgacca tgattacgcc aagcttgcac gctgcaggt  
4621 cgactctaga g

Fig 14 (cont'd)

WO 02/42323

PCT/EP01/13604




Fig 15(a)




Fig 15(b)

WO 02/42323

PCT/EP01/13604





Fig 16



WO 02/42323

PCT/EP01/13604

**Fig 17**

WO 02/42323

PCT/EP01/13604




Fig 18




Fig 19

WO 02/42323

PCT/EP01/13604





Fig 2D


WO 02/42323

PCT/EP01/13604

**Fig 21**

WO 02/42323

PCT/EP01/13604

**Fig 22:**

WO 02/42323

PCT/EP01/13604





Fig 23

WO 02/42323

PCT/EP01/13604

**Fig 24:****Emission spectrum of Thioredoxin-FP-Fusion protein pGR15 at 451nm  
excitation**

WO 02/42323

PCT/EP01/13604




Fig 25




WO 02/42323

PCT/EP01/13604

**Fig 26**

Excitation spectra of Thioredoxin-FP-Fusion protein pGR15 at 490nm emission



WO 02/42323

PCT/EP01/13604

List of pGR clones

pGR	FP #	book	vector	Insert	mutation	What ?
pGR1	FP106	165p67, 69	pCR-XL-TOPO	fr#34: RT-PCR with oGR32/oGR34 on RNA Ca (165p18)	non	Polythoa 2: Fluorescent colonies E. coli
pGR2	FP107	165p67, 69	pCR-XL-TOPO	fr#34: RT-PCR with oGR32/oGR34 on RNA Ca (165p18)	non	Polythoa 2: Fluorescent colonies E. coli
pGR3	FP159	165p72, 80	pET32A-EcoRI/XhoI	fr#55: oGR69/oGR70 on pGR8 (165p18)	N41D, 3' end	Polythoa 2: Fluorescent colonies E. coli
pGR4	FP164	165p72, 80	pCDNA3-EcoRI/XhoI	fr#55: oGR69/oGR70 on pGR8	N41D, 3' end	Polythoa 2: Fluorescence in COS
pGR5	FP167	165p72, 80	pCDNA3-EcoRI/XhoI	fr#56: oGR69/oGR71 on pGR8	N41D, 3' end	Polythoa 2: Fluorescence in COS
pGR6	FP136	165p72, 80	pDW2721-AscI/XhoI	fr#54: oGR74/oGR72 on pGR1	non	Polythoa 2: Fluorescence in C. elegans (and COS)
pGR7	FP148	165p72, 79	pET32A-EcoRI/XhoI	fr#53: oGR68/oGR72 on pGR1	Q135R	Polythoa 2: Fluorescence in E. coli
pGR8	FP116	165p67, 69	pCR-XL-TOPO	fr#36: RT-PCR with oGR36/oGR38 on RNA Ca (165p18)	N41D, 3' end	Polythoa 2: Fluorescence in E. coli
pGR9	FP236	195p40	pDW2721-NheI/FseI	fr#68: NheI/FseI fr of pGR16 (195p38)	I106T	synthetic worm polythoa 2
pGR10	FP237	195p40	pDW2721-NheI/FseI	fr#68: NheI/FseI fr of pGR16 (195p38)	I106T	synthetic worm polythoa 2: Fluorescence in C. elegans
pGR11	FP238	195p40	pDW2721-NheI/FseI	fr#73: NheI/FseI fr of FP211 (195p38)	insertion, 3 mutations	synthetic worm polythoa 2
pGR12	FP239	195p40	pDW2721-NheI/FseI	fr#74: NheI/FseI fr of FP212 (195p38)	deletion, mutation	synthetic worm polythoa 2
pGR13	FP320	195p72	pET32A-EcoRI/XhoI	Remutagenesis on pGR7 with oGR90/oGR91	non	backmutated pGR7: Polythoa 2: Fluorescence in E. coli

Fig 27

WO 02/42323

PCT/EP01/13604

pGR14	FP260	195p51, 53	pCR-XL-TOPO	fr#99: 525bp EcoRI/SnaI fr of pGR17 in 3736bp EcoRV fr of pGR1	NONE	Hybrid-Polyth2-Disco1: : Fluorescence in E. coli
pGR15	FP337	195p80	(pGR14)FP260- HindIII/EcoRI	fr#142: 124bp fr HindIII/EcoRI of pCDNA3.1/Hisa in 4212bp EcoRI/HindIII fr of pGR14	NONE	Hybrid-Polyth2-Disco1-His Tag: : Fluorescence in E. coli
pGR16	FP204	195p35	pCR-XL-TOPO	,synthetic fragment Entechelon: 195p32	I106T	synthetic worm polythoa 2
pGR17	FP176		pCR-XL-TOPO	fr #45: oGR39/oGR20 op SMART cDNA #16	NONE	'3 RACE Discosoma 1
pGR18	FP326	195p67, 68	pCDNA3-EcoRI/XhoI	fr#129: 705bp EcoRI/XhoI fr of pGR19 in pCDNA3/EcoRI/XhoI	NONE	Hybrid-Polyth2-Disco1: Fluorescence in COS
pGR19	FP312	195p67	pCRblunt	fr #117: oGR69/oGR96 on pGR14	NONE	Hybrid-Polyth2-Disco1: Fluorescence in E. coli
pGR20	FP325	195p68	pDW2700-AscI/XhoI	fr#128: 700bp AscI/XhoI fr of pGR21	K221N	Hybrid-Polyth2-Disco1: : Fluorescence in C. elegans
pGR21	FP309	195p67	pCR-XL-TOPO	oGR75/oGR96 on pGR14	K221N	Hybrid-Polyth2-Disco1: Fluorescence in E. coli
pGR22	FP217	195p22 till 28	pCR-XL-TOPO	fr#65: PCR op FP58 and FP84 with oGR33, oGR34, oGR92, oGR93	Silent Mutation	Polythoa 1
pGR23	FP241	195p43	pCR-XL-TOPO	oGR84/oGR85 on pGB3202	Unknown	eGFP: fluorescent colonies
pGR24	FP327	195p70	pCDNA3-EcoRI/XhoI	fr #133: EcoRI/XhoI fr of pGR26	none	Polythoa 1: Fluorescence in COS
pGR25	FP329	195p70	pET32A-EcoRI/XhoI	fr #133: EcoRI/XhoI fr of pGR26	none	Polythoa 1
pGR26	FP317	195p70	pCR-XL-TOPO	fr #121: oGR68/oGR72 on pGR22 (195p69)	NONE	Polythoa 1
pGR						
pGR						
pGR						
pGR						

Fig 27 (cont'd)

WO 02/42323

PCT/EP01/13604

clone pGR3:			wavelength at max fluorescence	% of max at different wavelengths
emission:				
at 452 nm excitation	Fig 15a		496nm	480nm = 30%; 525nm = 40%
at 469 nm excitation	Fig 16		496nm	480nm = 35%; 525nm = 40%
at 489 nm excitation	Fig 15b		496nm	480nm = 36%; 525nm = 40%
excitation				
at 490 nm emission	Fig 17		469nm	452nm = 64%; 456nm = 59%; 486nm = 47%; 489nm = 68%
clone pGR7:				
emission:				
at 452 nm excitation	Fig 19		490nm	480nm = 44%; 525nm = 37%
at 469 nm excitation	Fig 20		490nm	480nm = 51%; 525nm = 38%
excitation				
at 490 nm emission	Fig 18		469nm	440nm = 53%; 452nm = 60%; 456nm = 57%; 480nm = 53%
clone pGR13:				
Emission:				
at 452 nm excitation	Fig 21		490nm	480nm = 44%; 525nm = 37%
at 469 nm excitation	Fig 22		490nm	480nm = 51%; 525nm = 38%
excitation				
at 490 nm emission	Fig 23		469nm	440nm = 53%; 452nm = 60%; 456nm = 57%; 480nm = 53%
clone pGR15:				
emission:				
at 440 nm excitation	Fig 25		484nm	470nm = 54%; 525nm = 39%
at 451 nm excitation	Fig 24		484nm	470nm = 44%; 525nm = 36%
excitation				
at 484 nm emission	Fig 26		451nm	420nm = 66%; 440nm = 91%; 447nm = 89%; 470nm = 66%

Fig 28